Frozenize personal page - To The Moon

Frozenize

Frozenize

No personal profile

34Follow

6Followers

0Topic

0Badge

2021-08-18

$Tiger Brokers(TIGR)$it will go back up!

2021-08-05

$fuboTV Inc.(FUBO)$up up up

2021-08-03

$Netflix(NFLX)$just bought and it went down.... pray pray

2021-06-12

$fuboTV Inc.(FUBO)$is this a good buy ? what's the forecast of the growth?

2021-06-12

Hope for good news

Novavax says COVID-19 vaccine shows immune response against Beta virus variant

2021-06-12

Wow

Taiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.

2021-02-20

Great

Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity

2021-02-20

Interesting

Palantir: Buy The Dip

2021-02-13

Yes it's going up...

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3564012453009781","uuid":"3564012453009781","gmtCreate":1600920536696,"gmtModify":1612928981061,"name":"Frozenize","pinyin":"frozenize","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":34,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":9,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"61.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":833601604,"gmtCreate":1629230684608,"gmtModify":1676529971900,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>it will go back up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>it will go back up!&nbsp;","text":"$Tiger Brokers(TIGR)$it will go back up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833601604","isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890824957,"gmtCreate":1628093271079,"gmtModify":1703501191249,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>up up up","listText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>up up up","text":"$fuboTV Inc.(FUBO)$up up up","images":[{"img":"https://static.tigerbbs.com/2bf6ab4001e1206871c1c405c4d0d3a4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890824957","isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807304136,"gmtCreate":1627999273225,"gmtModify":1703499397388,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NFLX\">$Netflix(NFLX)$</a>just bought and it went down.... pray pray","listText":"<a href=\"https://laohu8.com/S/NFLX\">$Netflix(NFLX)$</a>just bought and it went down.... pray pray","text":"$Netflix(NFLX)$just bought and it went down.... pray pray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807304136","isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188425551,"gmtCreate":1623459738173,"gmtModify":1704204138323,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>is this a good buy ? what's the forecast of the growth?","listText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>is this a good buy ? what's the forecast of the growth?","text":"$fuboTV Inc.(FUBO)$is this a good buy ? what's the forecast of the growth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188425551","isVote":1,"tweetType":1,"viewCount":441,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188460160,"gmtCreate":1623459005050,"gmtModify":1704204113144,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Hope for good news","listText":"Hope for good news","text":"Hope for good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188460160","repostId":"2142202973","repostType":4,"repost":{"id":"2142202973","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623447457,"share":"https://ttm.financial/m/news/2142202973?lang=&edition=fundamental","pubTime":"2021-06-12 05:37","market":"us","language":"en","title":"Novavax says COVID-19 vaccine shows immune response against Beta virus variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2142202973","media":"Reuters","summary":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune respo","content":"<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID-19 vaccine shows immune response against Beta virus variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID-19 vaccine shows immune response against Beta virus variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 05:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142202973","content_text":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.\nThe vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.\nNovavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.\nThe company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.\nHowever, the response against the Beta variant was slightly less, Novavax said.\nThe European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.\nThe company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.\n(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188484480,"gmtCreate":1623458950140,"gmtModify":1704204111369,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188484480","repostId":"1135185071","repostType":4,"repost":{"id":"1135185071","pubTimestamp":1623425954,"share":"https://ttm.financial/m/news/1135185071?lang=&edition=fundamental","pubTime":"2021-06-11 23:39","market":"us","language":"en","title":"Taiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1135185071","media":"Barron's","summary":"A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars to the most advanced components that power high-end phones, computers, and data centers.Taiwan Semiconductor Manufacturing sits at the nexus of this global chip renaissance. The company is a critical supplier to U.S. technology giants likeApple andQualcomm and Chinese companies like Huawei Technolog","content":"<p><img src=\"https://static.tigerbbs.com/dc1ac5d314c0b0f304bf6c78a0f2b0c7\" tg-width=\"1260\" tg-height=\"840\">A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars to the most advanced components that power high-end phones, computers, and data centers.</p>\n<p>Taiwan Semiconductor Manufacturing(ticker: TSM) sits at the nexus of this global chip renaissance. The company is a critical supplier to U.S. technology giants likeApple(AAPL) andQualcomm(QCOM) and Chinese companies like Huawei Technologies. TSMC’s stock is widely held across the globe, and for good reason. It has returned an annualized 29% over the past decade.</p>\n<p>But TSMC shares are now caught up in a rare correction. The stock is down 15% since mid-February. Investors should avoid the temptation to buy on the dip, at least for now. A confluence of factors could make the next couple of quarters bumpy enough to give long-term investors a chance to scoop up shares of the tech juggernaut at an even cheaper price.</p>\n<p>To be sure, the long-term opportunity hasn’t changed. If oil was the crucial commodity of the past,semiconductors are the critical commodity of the future—and TSMC is a leader in making the advanced chips needed for 5G, artificial intelligence, cloud computing, and electric vehicles.</p>\n<p>Founded in 1987, the Taiwanese company accounts for roughly 60% of outsourced chip manufacturing and 90% of the profits. TSMC has made significant investment in its foundries, helping it manufacture ever-denser chips that generate more power while using less energy. RivalIntel(INTC) has struggled to match that success.</p>\n<p>Even the lone analyst with a Sell rating on TSMC stock sings the company’s praises: “This is an A-plus company with solid management,” says Mehdi Hosseini, senior equity analyst at Susquehanna Financial Group, who has covered TSMC for more than 20 years. But Hosseini says he can’t ignore the near-term challenges and the pricey stock.</p>\n<p>Despite the recent selloff, TSMC shares are still up 110% over the past 12 months, and they trade at 27 times earnings estimates for the next 12 months, well above the stock’s five-year average of 19.</p>\n<p><img src=\"https://static.tigerbbs.com/f343f4fd4554dcc3a5fc6842713fd34c\" tg-width=\"685\" tg-height=\"429\">That elevated multiple doesn’t offer much cushion if and when challenges arise. Some money managers caution that near-term demand may not live up to analysts’ rosy forecasts for the next couple of quarters. Also, increased spending by TSMC and its rivals to meet a surge in demand could dent profit margins.</p>\n<p>Meanwhile, escalating geopolitical tensions put Taiwan, a self-ruled democracy that China considers a province, and its most important company in a fraught position.</p>\n<p>Daiwa Capital Markets analyst Rick Hsu is concerned that the chip shortage—which has hobbled automotive plants and sent gamers scrambling to find new consoles—could create inventory-related issues in the first half of 2022.</p>\n<p>Hsu told<i>Barron’s</i>in an email that TSMC’s stock needs to shed another 15%, to about $100, to adequately reflect the current risk profile. The stock recently closed at $118.</p>\n<p>Lackluster demand related to smartphones, which accounts for 45% of revenue, could also lead to disappointment. With TSMC profit margins already near a peak, future growth will require a boost in sales. That could be challenging in the near term. Apple’s iPhone 13 is unlikely to offer a major catalyst, while Chinese smartphone vendors don’t currently have the killer app needed to drive upgrades, Hosseini says.</p>\n<p>“You can’t just give it multiple expansion because it’s a great company. You need earnings power,” Hosseini says, noting that the company trades at a significant premium to theS&amp;P 500 index.He has a price target of $85, putting him far outside the consensus. Wall Street’s average price target on TSMC is $141.</p>\n<p>Analysts, on average, expect TSMC’s earnings to increase 14% to $4.06 a share this year, and 16% to $4.69 a share next year, with revenue growing 16% to $55.8 billion this year, and another 16% next year.</p>\n<p><b>Chips on the Table</b></p>\n<p>Shares of Taiwan Semiconductor Manufacturing have returned an annual average of 25% over the last decade.</p>\n<p><img src=\"https://static.tigerbbs.com/5615dee32fa47048e8747447b01257c9\" tg-width=\"663\" tg-height=\"272\"></p>\n<p>In April, TSMC CEO C.C. Wei told investors of a structural increase in demand, with megatrends around 5G and high-performance computing applications fueling strong demand for several years to come.</p>\n<p>Even so, Wall Street’s estimates may be too optimistic, says Laura Geritz, CEO of Rondure Global Advisors, which owns TSMC shares. She notes that growth at the company was boosted last year as quarantined families loaded up on PCs, gadgets, gaming consoles, and home appliances, all of which require more and more chips.</p>\n<p>Those buying patterns could quickly change as the pandemic eases and central banks begin to taper their support of the economy.</p>\n<p>“I think you will get a better shot,” Geritz says of buying TSMC stock. “It’s expensive when you strip away what could be fiscal and stay-at-home economics.”</p>\n<p>One of the reasons that investors are drawn to TSMC is its deep and impressive list of customers. But that advantage is becoming increasingly costly to maintain as companies—and governments—push for more geographically diverse supply chains.</p>\n<p>In the U.S., the Senate just passed a sweeping $250 billion China package that includes funding and incentives for producing more chips closer to home, along with calls for increased funding of research and development more broadly to help the U.S. maintain its technological edge against China.</p>\n<p>The Biden administration just completed a supply-chain review of critical materials—such as chips—and is pushing to spur more production at home and make the U.S. less vulnerable to global supply-chain disruptions.</p>\n<p>The industry is already reacting. Intel recently unveiled plans to spend $20 billion on two new manufacturing plants in Arizona, whileSamsung Electronics(005930.Korea) plans to invest $116 billion over the next decade, which includes a new chip factory in the U.S. Meanwhile, TSMC has said it plans to invest $100 billion over the next three years—including building two new factories of its own in Arizona.</p>\n<p>The companies’ increased spending is probably required to maintain a competitive edge, and the expenditure could address some of the Biden administration concerns by moving some production back to the U.S.</p>\n<p>In the near term, though, the spending creates financial risk. Longtime TSMC investor Andrew Foster earlier this year sold the TSMC stake he held in his $2.1 billionSeafarer Overseas Growth and Incomefund (SFGIX). He cites concerns about the company’s increased capital expenditure and its potential impact on free cash flow and the dividend, which has a yield of 1.8%.</p>\n<p>Current valuations don’t account for those risks, according to Foster, who says he may reconsider if the stock gets cheaper.</p>\n<p>In an email, TSMC representative Nina Kao said the company’s investment in Arizona is intended to support customers’ long-term capacity needs and isn’t related to political pressure. The company, Kao added, is confident that the Arizona factory will be profitable.</p>\n<p>The biggest risk to TSMC shares is China. The country is intent on unification, and tensions have escalated with China increasing military activity in the South China Sea region. Friction is likely to intensify: The U.S. has said it willsoon hold investment and trade talks with Taiwan,as the administration looks to strengthen Taipei.</p>\n<p>While policy watchers don’t see an armed conflict on the horizon, therisk of an accident is rising as military activity mounts. How to quantify TSMC’s China risk keeps money managers up at night. They say that a military conflict between China and Taiwan is an all-bets-are-off event that would rattle entire markets, not just TSMC stock.</p>\n<p>TSMC declined to comment on politics beyond stating that it was a “law-abiding company” focused on serving its customers.</p>\n<p>The risks don’t change the fact that semiconductors have never been more important.</p>\n<p>“Valuations in quality growth names such as TSMC have clearly gone up, in part because demand for semiconductors is elevated, while at the same time there is quite a serious shortage of them,” says Martin Lau, managing partner at $37 billion FSSA Investment Managers, which is focused on Asia-Pacific and emerging market strategies.</p>\n<p>And yet, “cyclically, this is not the best time to buy TSMC, and the near-term margin of safety has fallen,” he adds. “We remain positive in the longer term.”</p>\n<p>Investors just have to pick the right entry point.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/taiwan-semi-stock-51623366589?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars ...</p>\n\n<a href=\"https://www.barrons.com/articles/taiwan-semi-stock-51623366589?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSM":"台积电"},"source_url":"https://www.barrons.com/articles/taiwan-semi-stock-51623366589?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135185071","content_text":"A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars to the most advanced components that power high-end phones, computers, and data centers.\nTaiwan Semiconductor Manufacturing(ticker: TSM) sits at the nexus of this global chip renaissance. The company is a critical supplier to U.S. technology giants likeApple(AAPL) andQualcomm(QCOM) and Chinese companies like Huawei Technologies. TSMC’s stock is widely held across the globe, and for good reason. It has returned an annualized 29% over the past decade.\nBut TSMC shares are now caught up in a rare correction. The stock is down 15% since mid-February. Investors should avoid the temptation to buy on the dip, at least for now. A confluence of factors could make the next couple of quarters bumpy enough to give long-term investors a chance to scoop up shares of the tech juggernaut at an even cheaper price.\nTo be sure, the long-term opportunity hasn’t changed. If oil was the crucial commodity of the past,semiconductors are the critical commodity of the future—and TSMC is a leader in making the advanced chips needed for 5G, artificial intelligence, cloud computing, and electric vehicles.\nFounded in 1987, the Taiwanese company accounts for roughly 60% of outsourced chip manufacturing and 90% of the profits. TSMC has made significant investment in its foundries, helping it manufacture ever-denser chips that generate more power while using less energy. RivalIntel(INTC) has struggled to match that success.\nEven the lone analyst with a Sell rating on TSMC stock sings the company’s praises: “This is an A-plus company with solid management,” says Mehdi Hosseini, senior equity analyst at Susquehanna Financial Group, who has covered TSMC for more than 20 years. But Hosseini says he can’t ignore the near-term challenges and the pricey stock.\nDespite the recent selloff, TSMC shares are still up 110% over the past 12 months, and they trade at 27 times earnings estimates for the next 12 months, well above the stock’s five-year average of 19.\nThat elevated multiple doesn’t offer much cushion if and when challenges arise. Some money managers caution that near-term demand may not live up to analysts’ rosy forecasts for the next couple of quarters. Also, increased spending by TSMC and its rivals to meet a surge in demand could dent profit margins.\nMeanwhile, escalating geopolitical tensions put Taiwan, a self-ruled democracy that China considers a province, and its most important company in a fraught position.\nDaiwa Capital Markets analyst Rick Hsu is concerned that the chip shortage—which has hobbled automotive plants and sent gamers scrambling to find new consoles—could create inventory-related issues in the first half of 2022.\nHsu toldBarron’sin an email that TSMC’s stock needs to shed another 15%, to about $100, to adequately reflect the current risk profile. The stock recently closed at $118.\nLackluster demand related to smartphones, which accounts for 45% of revenue, could also lead to disappointment. With TSMC profit margins already near a peak, future growth will require a boost in sales. That could be challenging in the near term. Apple’s iPhone 13 is unlikely to offer a major catalyst, while Chinese smartphone vendors don’t currently have the killer app needed to drive upgrades, Hosseini says.\n“You can’t just give it multiple expansion because it’s a great company. You need earnings power,” Hosseini says, noting that the company trades at a significant premium to theS&P 500 index.He has a price target of $85, putting him far outside the consensus. Wall Street’s average price target on TSMC is $141.\nAnalysts, on average, expect TSMC’s earnings to increase 14% to $4.06 a share this year, and 16% to $4.69 a share next year, with revenue growing 16% to $55.8 billion this year, and another 16% next year.\nChips on the Table\nShares of Taiwan Semiconductor Manufacturing have returned an annual average of 25% over the last decade.\n\nIn April, TSMC CEO C.C. Wei told investors of a structural increase in demand, with megatrends around 5G and high-performance computing applications fueling strong demand for several years to come.\nEven so, Wall Street’s estimates may be too optimistic, says Laura Geritz, CEO of Rondure Global Advisors, which owns TSMC shares. She notes that growth at the company was boosted last year as quarantined families loaded up on PCs, gadgets, gaming consoles, and home appliances, all of which require more and more chips.\nThose buying patterns could quickly change as the pandemic eases and central banks begin to taper their support of the economy.\n“I think you will get a better shot,” Geritz says of buying TSMC stock. “It’s expensive when you strip away what could be fiscal and stay-at-home economics.”\nOne of the reasons that investors are drawn to TSMC is its deep and impressive list of customers. But that advantage is becoming increasingly costly to maintain as companies—and governments—push for more geographically diverse supply chains.\nIn the U.S., the Senate just passed a sweeping $250 billion China package that includes funding and incentives for producing more chips closer to home, along with calls for increased funding of research and development more broadly to help the U.S. maintain its technological edge against China.\nThe Biden administration just completed a supply-chain review of critical materials—such as chips—and is pushing to spur more production at home and make the U.S. less vulnerable to global supply-chain disruptions.\nThe industry is already reacting. Intel recently unveiled plans to spend $20 billion on two new manufacturing plants in Arizona, whileSamsung Electronics(005930.Korea) plans to invest $116 billion over the next decade, which includes a new chip factory in the U.S. Meanwhile, TSMC has said it plans to invest $100 billion over the next three years—including building two new factories of its own in Arizona.\nThe companies’ increased spending is probably required to maintain a competitive edge, and the expenditure could address some of the Biden administration concerns by moving some production back to the U.S.\nIn the near term, though, the spending creates financial risk. Longtime TSMC investor Andrew Foster earlier this year sold the TSMC stake he held in his $2.1 billionSeafarer Overseas Growth and Incomefund (SFGIX). He cites concerns about the company’s increased capital expenditure and its potential impact on free cash flow and the dividend, which has a yield of 1.8%.\nCurrent valuations don’t account for those risks, according to Foster, who says he may reconsider if the stock gets cheaper.\nIn an email, TSMC representative Nina Kao said the company’s investment in Arizona is intended to support customers’ long-term capacity needs and isn’t related to political pressure. The company, Kao added, is confident that the Arizona factory will be profitable.\nThe biggest risk to TSMC shares is China. The country is intent on unification, and tensions have escalated with China increasing military activity in the South China Sea region. Friction is likely to intensify: The U.S. has said it willsoon hold investment and trade talks with Taiwan,as the administration looks to strengthen Taipei.\nWhile policy watchers don’t see an armed conflict on the horizon, therisk of an accident is rising as military activity mounts. How to quantify TSMC’s China risk keeps money managers up at night. They say that a military conflict between China and Taiwan is an all-bets-are-off event that would rattle entire markets, not just TSMC stock.\nTSMC declined to comment on politics beyond stating that it was a “law-abiding company” focused on serving its customers.\nThe risks don’t change the fact that semiconductors have never been more important.\n“Valuations in quality growth names such as TSMC have clearly gone up, in part because demand for semiconductors is elevated, while at the same time there is quite a serious shortage of them,” says Martin Lau, managing partner at $37 billion FSSA Investment Managers, which is focused on Asia-Pacific and emerging market strategies.\nAnd yet, “cyclically, this is not the best time to buy TSMC, and the near-term margin of safety has fallen,” he adds. “We remain positive in the longer term.”\nInvestors just have to pick the right entry point.","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387581168,"gmtCreate":1613754675754,"gmtModify":1704884740157,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387581168","repostId":"2112849691","repostType":2,"repost":{"id":"2112849691","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1613751540,"share":"https://ttm.financial/m/news/2112849691?lang=&edition=fundamental","pubTime":"2021-02-20 00:19","market":"hk","language":"en","title":"Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2112849691","media":"Dow Jones","summary":"MW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine ","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n</p>\n<p>\n  Ciara Linnane \n</p>\n<p>\n  U.S. will commit $4 billion to the World Health Organization's Covax program \n</p>\n<p>\n  The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 110.4 million on Friday, as the leaders of the G-7 economies were scheduled to meet and discuss the effort to get COVID vaccines to the world's poorest countries. \n</p>\n<p>\n  The administration of President Joe Biden said it will commit $4 billion to the World Health Organization's Covax program, which aims to ensure vaccine equity for lower-income countries, which so far have been left behind as wealthier countries have snapped up the bulk of the vaccine supply. \n</p>\n<p>\n  The European Union said it will double its Covax funding to <a href=\"https://laohu8.com/S/AONE\">one</a> billion euros and pledged another 100 million that will be earmarked for African countries. In an interview with the Financial Times, French President Emmanuel Macron proposed that Western countries transfer 3% to 5% of their stock of vaccine to Africa. \n</p>\n<p>\n  The U.K. holds the G-7 presidency this year, and Prime Minister Boris Johnson is meeting virtually with the leaders of France, Germany, Italy, Canada, Japan and the United States to discuss international challenges -- chief among them the pandemic that has killed almost 2.5 million people around the world, the Associated Press reported . \n</p>\n<p>\n</p>\n<p>\n  The head of the United Nations on Thursday sharply criticized developed countries for hogging COVID-19 vaccines  and called for a global effort to get all people in all countries vaccinated as soon as possible. \n</p>\n<p>\n  UN Secretary-General António Guterres slammed the \"wildly uneven and unfair\" distribution of vaccines, with 10 countries administering 75% of all vaccinations to date, leaving 130 countries without a single dose. \n</p>\n<p>\n  Guterres comments echo those of World Health Organization Director-General Tedros Adhanom Ghebreyesus, who has repeatedly called on richer nations to join the WHO's Covax program,  which aims to ensure vaccine supply for lower-income countries. The agency says Covax needs $5 billion in funding in 2021 alone. \n</p>\n<p>\n  \"We need global leadership to scale up vaccine production and achieve vaccine equity,\" Tedros said in a joint statement issued last week with UNICEF Executive Director Henrietta Fore. \"COVID-19 has shown that our fates are inextricably linked. Whether we win or lose, we will do so together.\" \n</p>\n<p>\n  Don't miss: Hoarding the COVID vaccines is a losing strategy for rich nations  \n</p>\n<p>\n</p>\n<p>\n  On Friday, Tedros welcomed the new commitments to Covax. \n</p>\n<p>\n  \"This can't be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,\" he said in a statement.   \n</p>\n<p>\n  There was positive vaccine news from Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX), which said they are requesting a regulatory change to the storage requirements for their COVID-19 vaccine, as MarketWatch's Jaimy Lee reported . \n</p>\n<p>\n  Don't miss: Yes, your employer can require you to get a COVID-19 vaccine, the EEOC says  \n</p>\n<p>\n  The companies said they have new data showing their vaccine is still stable when stored in pharmaceutical freezers and refrigerators for up to two weeks, between the temperatures of negative 13 degrees Fahrenheit and 5 degrees Fahrenheit. Right now their vaccine must be stored in ultra-low temperature freezers between the temperatures of negative 112 degrees Fahrenheit and negative 76 degrees Fahrenheit. \n</p>\n<p>\n  \"The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,\" BioNTech CEO Ugur Sahin said in a statement. \n</p>\n<p>\n  Separately, Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> said it has submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. J&amp;J's vaccine will be reviewed by a group of vaccine experts next week as part of the U.S. Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. \n</p>\n<p>\n  A Mayo Clinic report found that both of the vaccines authorized for use in the U.S. -- the Pfizer/BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a> and a separate one developed by Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> that uses the same mRNA technology -- are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials. \n</p>\n<p>\n  The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. \n</p>\n<p>\n</p>\n<p>\n  In other news: \n</p>\n<p>\n  -- Life should return to normal -- more or less -- by Christmas, Dr. Anthony Fauci predicted Thursday. In an interview with MSNBC that things will start getting back to normal \"by the end of the year, by Christmas.\" It may not be exactly like pre-pandemic life, though. Fauci said theaters and restaurants will likely still have reduced capacity, and \"Maybe you'll still have to wear masks\" in public. \n</p>\n<p>\n  Read now: How COVID-19 is keeping kids away from the dentist -- especially children on Medicaid  \n</p>\n<p>\n  -- It's very rare for someone to get infected with the coronavirus causing the disease COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn't guaranteed  51 confirmed cases of reinfection along with roughly 11,000 suspected or probable reinfections. Reinfection is thought to occur when protective antibodies wane in people who have previously contracted the virus or in people who contracted the virus without developing antibodies. \n</p>\n<p>\n  --New York Gov. Andrew Cuomo, who was widely praised for his handling to the pandemic when his state was the epicenter last spring, is facing a growing chorus of criticism over his administration's failure   about his conversation with the governor. \n</p>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  February 19, 2021 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-02-20 00:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n</p>\n<p>\n  Ciara Linnane \n</p>\n<p>\n  U.S. will commit $4 billion to the World Health Organization's Covax program \n</p>\n<p>\n  The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 110.4 million on Friday, as the leaders of the G-7 economies were scheduled to meet and discuss the effort to get COVID vaccines to the world's poorest countries. \n</p>\n<p>\n  The administration of President Joe Biden said it will commit $4 billion to the World Health Organization's Covax program, which aims to ensure vaccine equity for lower-income countries, which so far have been left behind as wealthier countries have snapped up the bulk of the vaccine supply. \n</p>\n<p>\n  The European Union said it will double its Covax funding to <a href=\"https://laohu8.com/S/AONE\">one</a> billion euros and pledged another 100 million that will be earmarked for African countries. In an interview with the Financial Times, French President Emmanuel Macron proposed that Western countries transfer 3% to 5% of their stock of vaccine to Africa. \n</p>\n<p>\n  The U.K. holds the G-7 presidency this year, and Prime Minister Boris Johnson is meeting virtually with the leaders of France, Germany, Italy, Canada, Japan and the United States to discuss international challenges -- chief among them the pandemic that has killed almost 2.5 million people around the world, the Associated Press reported . \n</p>\n<p>\n</p>\n<p>\n  The head of the United Nations on Thursday sharply criticized developed countries for hogging COVID-19 vaccines  and called for a global effort to get all people in all countries vaccinated as soon as possible. \n</p>\n<p>\n  UN Secretary-General António Guterres slammed the \"wildly uneven and unfair\" distribution of vaccines, with 10 countries administering 75% of all vaccinations to date, leaving 130 countries without a single dose. \n</p>\n<p>\n  Guterres comments echo those of World Health Organization Director-General Tedros Adhanom Ghebreyesus, who has repeatedly called on richer nations to join the WHO's Covax program,  which aims to ensure vaccine supply for lower-income countries. The agency says Covax needs $5 billion in funding in 2021 alone. \n</p>\n<p>\n  \"We need global leadership to scale up vaccine production and achieve vaccine equity,\" Tedros said in a joint statement issued last week with UNICEF Executive Director Henrietta Fore. \"COVID-19 has shown that our fates are inextricably linked. Whether we win or lose, we will do so together.\" \n</p>\n<p>\n  Don't miss: Hoarding the COVID vaccines is a losing strategy for rich nations  \n</p>\n<p>\n</p>\n<p>\n  On Friday, Tedros welcomed the new commitments to Covax. \n</p>\n<p>\n  \"This can't be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,\" he said in a statement.   \n</p>\n<p>\n  There was positive vaccine news from Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX), which said they are requesting a regulatory change to the storage requirements for their COVID-19 vaccine, as MarketWatch's Jaimy Lee reported . \n</p>\n<p>\n  Don't miss: Yes, your employer can require you to get a COVID-19 vaccine, the EEOC says  \n</p>\n<p>\n  The companies said they have new data showing their vaccine is still stable when stored in pharmaceutical freezers and refrigerators for up to two weeks, between the temperatures of negative 13 degrees Fahrenheit and 5 degrees Fahrenheit. Right now their vaccine must be stored in ultra-low temperature freezers between the temperatures of negative 112 degrees Fahrenheit and negative 76 degrees Fahrenheit. \n</p>\n<p>\n  \"The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,\" BioNTech CEO Ugur Sahin said in a statement. \n</p>\n<p>\n  Separately, Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> said it has submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. J&amp;J's vaccine will be reviewed by a group of vaccine experts next week as part of the U.S. Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. \n</p>\n<p>\n  A Mayo Clinic report found that both of the vaccines authorized for use in the U.S. -- the Pfizer/BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a> and a separate one developed by Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> that uses the same mRNA technology -- are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials. \n</p>\n<p>\n  The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. \n</p>\n<p>\n</p>\n<p>\n  In other news: \n</p>\n<p>\n  -- Life should return to normal -- more or less -- by Christmas, Dr. Anthony Fauci predicted Thursday. In an interview with MSNBC that things will start getting back to normal \"by the end of the year, by Christmas.\" It may not be exactly like pre-pandemic life, though. Fauci said theaters and restaurants will likely still have reduced capacity, and \"Maybe you'll still have to wear masks\" in public. \n</p>\n<p>\n  Read now: How COVID-19 is keeping kids away from the dentist -- especially children on Medicaid  \n</p>\n<p>\n  -- It's very rare for someone to get infected with the coronavirus causing the disease COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn't guaranteed  51 confirmed cases of reinfection along with roughly 11,000 suspected or probable reinfections. Reinfection is thought to occur when protective antibodies wane in people who have previously contracted the virus or in people who contracted the virus without developing antibodies. \n</p>\n<p>\n  --New York Gov. Andrew Cuomo, who was widely praised for his handling to the pandemic when his state was the epicenter last spring, is facing a growing chorus of criticism over his administration's failure   about his conversation with the governor. \n</p>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  February 19, 2021 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞","JNJ":"强生"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112849691","content_text":"MW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n\n\n  Ciara Linnane \n\n\n  U.S. will commit $4 billion to the World Health Organization's Covax program \n\n\n  The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 110.4 million on Friday, as the leaders of the G-7 economies were scheduled to meet and discuss the effort to get COVID vaccines to the world's poorest countries. \n\n\n  The administration of President Joe Biden said it will commit $4 billion to the World Health Organization's Covax program, which aims to ensure vaccine equity for lower-income countries, which so far have been left behind as wealthier countries have snapped up the bulk of the vaccine supply. \n\n\n  The European Union said it will double its Covax funding to one billion euros and pledged another 100 million that will be earmarked for African countries. In an interview with the Financial Times, French President Emmanuel Macron proposed that Western countries transfer 3% to 5% of their stock of vaccine to Africa. \n\n\n  The U.K. holds the G-7 presidency this year, and Prime Minister Boris Johnson is meeting virtually with the leaders of France, Germany, Italy, Canada, Japan and the United States to discuss international challenges -- chief among them the pandemic that has killed almost 2.5 million people around the world, the Associated Press reported . \n\n\n\n\n  The head of the United Nations on Thursday sharply criticized developed countries for hogging COVID-19 vaccines  and called for a global effort to get all people in all countries vaccinated as soon as possible. \n\n\n  UN Secretary-General António Guterres slammed the \"wildly uneven and unfair\" distribution of vaccines, with 10 countries administering 75% of all vaccinations to date, leaving 130 countries without a single dose. \n\n\n  Guterres comments echo those of World Health Organization Director-General Tedros Adhanom Ghebreyesus, who has repeatedly called on richer nations to join the WHO's Covax program,  which aims to ensure vaccine supply for lower-income countries. The agency says Covax needs $5 billion in funding in 2021 alone. \n\n\n  \"We need global leadership to scale up vaccine production and achieve vaccine equity,\" Tedros said in a joint statement issued last week with UNICEF Executive Director Henrietta Fore. \"COVID-19 has shown that our fates are inextricably linked. Whether we win or lose, we will do so together.\" \n\n\n  Don't miss: Hoarding the COVID vaccines is a losing strategy for rich nations  \n\n\n\n\n  On Friday, Tedros welcomed the new commitments to Covax. \n\n\n  \"This can't be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,\" he said in a statement.   \n\n\n  There was positive vaccine news from Pfizer Inc. $(PFE)$ and its German partner BioNTech SE (BNTX), which said they are requesting a regulatory change to the storage requirements for their COVID-19 vaccine, as MarketWatch's Jaimy Lee reported . \n\n\n  Don't miss: Yes, your employer can require you to get a COVID-19 vaccine, the EEOC says  \n\n\n  The companies said they have new data showing their vaccine is still stable when stored in pharmaceutical freezers and refrigerators for up to two weeks, between the temperatures of negative 13 degrees Fahrenheit and 5 degrees Fahrenheit. Right now their vaccine must be stored in ultra-low temperature freezers between the temperatures of negative 112 degrees Fahrenheit and negative 76 degrees Fahrenheit. \n\n\n  \"The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,\" BioNTech CEO Ugur Sahin said in a statement. \n\n\n  Separately, Johnson & Johnson $(JNJ)$ said it has submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. J&J's vaccine will be reviewed by a group of vaccine experts next week as part of the U.S. Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. \n\n\n  A Mayo Clinic report found that both of the vaccines authorized for use in the U.S. -- the Pfizer/BioNTech one and a separate one developed by Moderna Inc. $(MRNA)$ that uses the same mRNA technology -- are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials. \n\n\n  The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. \n\n\n\n\n  In other news: \n\n\n  -- Life should return to normal -- more or less -- by Christmas, Dr. Anthony Fauci predicted Thursday. In an interview with MSNBC that things will start getting back to normal \"by the end of the year, by Christmas.\" It may not be exactly like pre-pandemic life, though. Fauci said theaters and restaurants will likely still have reduced capacity, and \"Maybe you'll still have to wear masks\" in public. \n\n\n  Read now: How COVID-19 is keeping kids away from the dentist -- especially children on Medicaid  \n\n\n  -- It's very rare for someone to get infected with the coronavirus causing the disease COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn't guaranteed  51 confirmed cases of reinfection along with roughly 11,000 suspected or probable reinfections. Reinfection is thought to occur when protective antibodies wane in people who have previously contracted the virus or in people who contracted the virus without developing antibodies. \n\n\n  --New York Gov. Andrew Cuomo, who was widely praised for his handling to the pandemic when his state was the epicenter last spring, is facing a growing chorus of criticism over his administration's failure   about his conversation with the governor. \n\n\n  (MORE TO FOLLOW) Dow Jones Newswires\n\n\n  February 19, 2021 11:19 ET (16:19 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387583889,"gmtCreate":1613754611841,"gmtModify":1704884739025,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387583889","repostId":"1100960455","repostType":4,"repost":{"id":"1100960455","pubTimestamp":1613717993,"share":"https://ttm.financial/m/news/1100960455?lang=&edition=fundamental","pubTime":"2021-02-19 14:59","market":"us","language":"en","title":"Palantir: Buy The Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1100960455","media":"Seeking Alpha","summary":"Summary\n\nPalantir posted solid revenue, but missed on earnings. The future forecast was a bit disapp","content":"<p>Summary</p>\n<ul>\n <li>Palantir posted solid revenue, but missed on earnings. The future forecast was a bit disappointing.</li>\n <li>Palantir is expecting 30% year-over-year revenue growth after posting 47% growth for 2020.</li>\n <li>Palantir continues to grow its client base across multiple industries.</li>\n <li>Palantir's lock-up period ends on February 19th. Place your bets!</li>\n</ul>\n<p>One of the hotter stocks as of late is recent Direct Listing, Palantir Technologies Inc. (PLTR). Some investors were expecting the company was expected to release blowout earnings today and fell short of that. The company did post incredible revenue growth, and the path forward looks bright as well. However, investors were disappointed with just how bright that picture is according to the company. The stock is falling leading up to the end of the lock-up period as expected. Next week will tell a better story as to where this stock is headed. If you are feeling risky, jump aboard.</p>\n<p><b>Who Are They?</b></p>\n<p>If you are like me, you likely had no idea who this company was or what they did. Well, Palantir Technologies Inc. has been around since 2003 and is headquartered in Denver, Colorado. In short,they build and deploy software platforms for the intelligence community in the USA to assist in counterterrorism investigations and operations.</p>\n<p>Palantir Gothamis a software program that identifies patterns hidden deep within datasets. This helps execute real-world responses to threats that have been identified within the platform. This was used in the efforts to help those in need in hurricane Florence in 2018. Palantir Gothamcombined publicly available flood data with weather information and social vulnerability census data to find the communities in greatest needand resources were deployed appropriately. More recently, they are providing the U.S. government with coronavirus tracking software.</p>\n<p>The company also provides Palantir Foundry,a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place.</p>\n<p>Pretty cool hey?</p>\n<p><b>What Is Driving The Company?</b></p>\n<p>Revenue. This is a growth play, plain and simple. Looking below we can see what is forecasted down the pipe. The missing block is 2020, which we found out todaywas $1.1 billion. That is a ~47% increase year-over-year. Going forward, analysts are projecting the pace stays heavy at 35%+ per year revenue growth. Often we consider 20% being strong, so that makes this look really good. For the fourth quarter, the company posted $322.1 million in revenue for the quarter, which was a beat by 20%.</p>\n<p><img src=\"https://static.tigerbbs.com/2926257ca97794e55159ce8c6021a745\" tg-width=\"2978\" tg-height=\"992\"></p>\n<p>(Source: TIKR.com)</p>\n<p>The shock came from theloss per share which totaled $0.08 versus the positive $0.02 consensus. The stock fell over 12% today on the earnings news. Upon diving deeper, it would appear most investors were disappointed with the forward forecasts. I personally think they are sandbagging a bit to blow away consensus down the line, but time will tell how true that is. Based on everything the company had put out in terms of news, which is nicely outlined inJohn Rhodes article : Palantir: Potential Q4 Revenue Blowoutmost people expected the revenue beat, but the action in the stock over the last week showed otherwise.</p>\n<p>Data has become more relevant to the average person than ever before. The local news has all kinds of data on it when it comes to COVID-19.In 2020, Palantir helped 100 commercial organizations and 10 national governments respond to COVID-19. This has been a large opportunity for Palantir, and they have not squandered it. This response has helped earn thema 2-year contract for U.K. health services work worth $31.5 million. In the fourth quarter alone, the company signed21 deals worth more than $5 million. 12 of which were worth $10 million or more. Revenue growth will continue to be the future of Palantir.</p>\n<p>Some of the best business going is government business. For the year, Palantir saw56% of their revenue or $610 million come from government contracts. While the commercial side saw higher year-over-year growth at 107%, a 77% increase in government-based revenue isn't anything to laugh at. One of the more impressive pieces was that we saw happen with the average customer.Revenue increased by 41% year-over-year. Up to $7.9 million per customer from $5.6 million. This is an important metric to keep an eye on as customers hand more and more business over to Palantir as they continue to develop and improve their systems. The other factor playing into this is Palantir pulling larger customers into the fold. The new customers acquired in 2020, generated $42 million in revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/9284f5fd3e26d0c55fcd9b2f6355371e\" tg-width=\"1752\" tg-height=\"983\"></p>\n<p>(Company Presentation)</p>\n<p>So all of this and we still sit down 12% today? As I mentioned above, it was the forward forecasts that people were a bit shocked at. Palantir said toexpect revenue growth in excess of 30% for 2021. This would be fantastic news for most companies, but after you just posted a 47% growth year, it is a bit saddening. But as I said, I think they are sandbagging a bit. Analysts are still projecting about a 35% increase for 2021. Something tells me they will outdo that as the year goes on. The company did state that they are targeting $4 billion in revenue by 2025, which carrying 30% per year growth from here will get you. I fully expect that number to creep closer to $5 billion based on current projections. Palantir is going after the \"big fish\" across multiple industries.8 of their customers fall into the Fortune 100, and 12 of the Global 100. As their products continue to develop and improve, their bottom line is only going to get better. I think there is a lot of room to run here in the long term.</p>\n<p><b>What Are The Risks?</b></p>\n<p>One of the up-and-coming risks is the lock-up period ending, which I will touch on below. Besides that, I will look at the government contracts. Yes, they are some of the most important, but that's not to say they come without risk. In the past, Palantir has said they need to focus more so on commercial customers to help the bottom line and to turn a profit (part of the reason for the earnings sell-off). As we can see, they have landed some big-time commercial clients, but that government aspect still exists.</p>\n<p>Something to keep in mind as well is that dealing with the government can lead to crossing some lines that some are not okay with. As reported by the Washington Post,in 2018, more than 200 employees signed a letter to CEO Alex Karp, citing concerns over a partnership with Immigration and Customs Enforcement. Multiple other big tech companies have been forced to cut ties with government agencies in the past over potential human rights violations.</p>\n<p>That said, I do really think the company will continue to do very well in the commercial sector and well reduce the overall government exposure overtime.</p>\n<p><b>What's The \"Lock-Up Period\"?</b></p>\n<p>The one concern many have had with Palantir is the lock-up period, which ends on February 19th (Friday). Typically, this is where we will see the lows kick in on IPO's that go this route, but it is not always the case.</p>\n<blockquote>\n Looking at 15 stocks that sawtheir lock-up periods expire in the first two weeks of October, the majority of shares started to fall in the days before the expiration date, prior to bouncing back three to five days afterwards. However, some saw virtually no selling pressure on the day and the share price immediately climbed once the lock-up had ended.\n</blockquote>\n<p>What is it? Well in short, instead of an IPO where new shares of the company are created and are underwritten by an intermediary, we have a Direct Listing. This is wherethe business sells shares directly to the public without the help of any intermediaries. It does not involve any underwriters or other intermediaries, there are no new shares issued. This means the largest shareholders in the business can only freely sell their shares after the IPO lock-up expiration. Spotify (SPOT) and Slack (WORK) are two examples of companies that went the Direct Listing route. That said, neither of these companies had lock-up periods for employees.</p>\n<p>So what does this mean? Well, given thatMarketWatch said:</p>\n<blockquote>\n For Palantir, though, years of venture-capital investments have created more than enough shares to launch public trading: roughly 1.64 billion, though that grows to 2.17 billion in a fully diluted formula that includes vesting options.\n</blockquote>\n<p>It means that with roughly 497 million current outstanding shares, that we could see about 1.7 billion shares hit the market. Now that is not really likely, but what it does mean is that there should be less than average selling pressure on the stock considering the usually IPO accounts for 10% of shares released, while Palantir released over 20% based on the numbers provided above.</p>\n<p>Where are we now? Well as per the study quoted earlier, we are right on track. The stock is selling off in an orderly fashion right before the lock-up period ends. Now we have to wait and see what the rebound looks like. Or does everyone sell high and try and buy even lower? It is a bit of a wait-and-see. Let's take a look at what the technicals show us.</p>\n<p><b>What Does The Price Say?</b></p>\n<p>Taking a quick peek at the technicals, we can see a couple of really strong support levels. Firstly, we broke through a pretty big one at $30 today and did so in a big way, which is a bit concerning in the short term, but there is potential for a quick bounce to re-test that $30 mark quickly. If these markets have taught us anything, it's that they can move quickly! In a normal case, this is probably where my stop would be. But have not had a position until today, the game changes a bit as I take on more risk.</p>\n<p><img src=\"https://static.tigerbbs.com/6b568bf73db2c1b38aaa1546a10427dc\" tg-width=\"3837\" tg-height=\"1813\"></p>\n<p>(Source: TC2000.com)</p>\n<p>When a stock as popular as Palantir tanks like we saw today, one of two things happens. Either the dip gets bought up and this stock will fly back up to $40, or we see Palantir drop down to ~$23. Because the stock is so new, we really do not have a good gauge for support. Looking below we can see roughly where I am pulling $23 out of. This is a pretty substantial move from here yet. Would be about 20% to the downside. If $23 breaks, it could go even further south.</p>\n<p><img src=\"https://static.tigerbbs.com/3e3505c465c407b7387cbedf16a1b233\" tg-width=\"3840\" tg-height=\"1808\"></p>\n<p>(Source: TC2000.com)</p>\n<p>When trying to catch the bounce, you have to be prepared to average down. It is a totally different approach. Scale in, and scale-out.... all while knowing when to cut it loose. If you want to play this safe, watch for the bounce and try and get in then. I do think there will be a decent bounce that takes the stock back to $36-$40, but the question is when. This is not a long-term hold for me personally.</p>\n<p><b>Wrap-Up</b></p>\n<p>As you can see, there is a lot to like about the direction in which the company is headed. The valuation can always be debated, but at the end of the day, the value is whatever someone is willing to pay for it. Palantir is a revenue machine and it is not going to slow down. They are playing with the \"big fish\" and the revenue will follow as long as they can continue to deliver on their goals. I am currently long, but watching closely as the lock-up period ends this week. If you are going long, make sure to scale in over the next couple of days and place your bets for which way this goes next week. Stay safe out there!</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Buy The Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Buy The Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-19 14:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4406809-palantir-buy-the-dip><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir posted solid revenue, but missed on earnings. The future forecast was a bit disappointing.\nPalantir is expecting 30% year-over-year revenue growth after posting 47% growth for 2020.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4406809-palantir-buy-the-dip\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4406809-palantir-buy-the-dip","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100960455","content_text":"Summary\n\nPalantir posted solid revenue, but missed on earnings. The future forecast was a bit disappointing.\nPalantir is expecting 30% year-over-year revenue growth after posting 47% growth for 2020.\nPalantir continues to grow its client base across multiple industries.\nPalantir's lock-up period ends on February 19th. Place your bets!\n\nOne of the hotter stocks as of late is recent Direct Listing, Palantir Technologies Inc. (PLTR). Some investors were expecting the company was expected to release blowout earnings today and fell short of that. The company did post incredible revenue growth, and the path forward looks bright as well. However, investors were disappointed with just how bright that picture is according to the company. The stock is falling leading up to the end of the lock-up period as expected. Next week will tell a better story as to where this stock is headed. If you are feeling risky, jump aboard.\nWho Are They?\nIf you are like me, you likely had no idea who this company was or what they did. Well, Palantir Technologies Inc. has been around since 2003 and is headquartered in Denver, Colorado. In short,they build and deploy software platforms for the intelligence community in the USA to assist in counterterrorism investigations and operations.\nPalantir Gothamis a software program that identifies patterns hidden deep within datasets. This helps execute real-world responses to threats that have been identified within the platform. This was used in the efforts to help those in need in hurricane Florence in 2018. Palantir Gothamcombined publicly available flood data with weather information and social vulnerability census data to find the communities in greatest needand resources were deployed appropriately. More recently, they are providing the U.S. government with coronavirus tracking software.\nThe company also provides Palantir Foundry,a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place.\nPretty cool hey?\nWhat Is Driving The Company?\nRevenue. This is a growth play, plain and simple. Looking below we can see what is forecasted down the pipe. The missing block is 2020, which we found out todaywas $1.1 billion. That is a ~47% increase year-over-year. Going forward, analysts are projecting the pace stays heavy at 35%+ per year revenue growth. Often we consider 20% being strong, so that makes this look really good. For the fourth quarter, the company posted $322.1 million in revenue for the quarter, which was a beat by 20%.\n\n(Source: TIKR.com)\nThe shock came from theloss per share which totaled $0.08 versus the positive $0.02 consensus. The stock fell over 12% today on the earnings news. Upon diving deeper, it would appear most investors were disappointed with the forward forecasts. I personally think they are sandbagging a bit to blow away consensus down the line, but time will tell how true that is. Based on everything the company had put out in terms of news, which is nicely outlined inJohn Rhodes article : Palantir: Potential Q4 Revenue Blowoutmost people expected the revenue beat, but the action in the stock over the last week showed otherwise.\nData has become more relevant to the average person than ever before. The local news has all kinds of data on it when it comes to COVID-19.In 2020, Palantir helped 100 commercial organizations and 10 national governments respond to COVID-19. This has been a large opportunity for Palantir, and they have not squandered it. This response has helped earn thema 2-year contract for U.K. health services work worth $31.5 million. In the fourth quarter alone, the company signed21 deals worth more than $5 million. 12 of which were worth $10 million or more. Revenue growth will continue to be the future of Palantir.\nSome of the best business going is government business. For the year, Palantir saw56% of their revenue or $610 million come from government contracts. While the commercial side saw higher year-over-year growth at 107%, a 77% increase in government-based revenue isn't anything to laugh at. One of the more impressive pieces was that we saw happen with the average customer.Revenue increased by 41% year-over-year. Up to $7.9 million per customer from $5.6 million. This is an important metric to keep an eye on as customers hand more and more business over to Palantir as they continue to develop and improve their systems. The other factor playing into this is Palantir pulling larger customers into the fold. The new customers acquired in 2020, generated $42 million in revenue.\n\n(Company Presentation)\nSo all of this and we still sit down 12% today? As I mentioned above, it was the forward forecasts that people were a bit shocked at. Palantir said toexpect revenue growth in excess of 30% for 2021. This would be fantastic news for most companies, but after you just posted a 47% growth year, it is a bit saddening. But as I said, I think they are sandbagging a bit. Analysts are still projecting about a 35% increase for 2021. Something tells me they will outdo that as the year goes on. The company did state that they are targeting $4 billion in revenue by 2025, which carrying 30% per year growth from here will get you. I fully expect that number to creep closer to $5 billion based on current projections. Palantir is going after the \"big fish\" across multiple industries.8 of their customers fall into the Fortune 100, and 12 of the Global 100. As their products continue to develop and improve, their bottom line is only going to get better. I think there is a lot of room to run here in the long term.\nWhat Are The Risks?\nOne of the up-and-coming risks is the lock-up period ending, which I will touch on below. Besides that, I will look at the government contracts. Yes, they are some of the most important, but that's not to say they come without risk. In the past, Palantir has said they need to focus more so on commercial customers to help the bottom line and to turn a profit (part of the reason for the earnings sell-off). As we can see, they have landed some big-time commercial clients, but that government aspect still exists.\nSomething to keep in mind as well is that dealing with the government can lead to crossing some lines that some are not okay with. As reported by the Washington Post,in 2018, more than 200 employees signed a letter to CEO Alex Karp, citing concerns over a partnership with Immigration and Customs Enforcement. Multiple other big tech companies have been forced to cut ties with government agencies in the past over potential human rights violations.\nThat said, I do really think the company will continue to do very well in the commercial sector and well reduce the overall government exposure overtime.\nWhat's The \"Lock-Up Period\"?\nThe one concern many have had with Palantir is the lock-up period, which ends on February 19th (Friday). Typically, this is where we will see the lows kick in on IPO's that go this route, but it is not always the case.\n\n Looking at 15 stocks that sawtheir lock-up periods expire in the first two weeks of October, the majority of shares started to fall in the days before the expiration date, prior to bouncing back three to five days afterwards. However, some saw virtually no selling pressure on the day and the share price immediately climbed once the lock-up had ended.\n\nWhat is it? Well in short, instead of an IPO where new shares of the company are created and are underwritten by an intermediary, we have a Direct Listing. This is wherethe business sells shares directly to the public without the help of any intermediaries. It does not involve any underwriters or other intermediaries, there are no new shares issued. This means the largest shareholders in the business can only freely sell their shares after the IPO lock-up expiration. Spotify (SPOT) and Slack (WORK) are two examples of companies that went the Direct Listing route. That said, neither of these companies had lock-up periods for employees.\nSo what does this mean? Well, given thatMarketWatch said:\n\n For Palantir, though, years of venture-capital investments have created more than enough shares to launch public trading: roughly 1.64 billion, though that grows to 2.17 billion in a fully diluted formula that includes vesting options.\n\nIt means that with roughly 497 million current outstanding shares, that we could see about 1.7 billion shares hit the market. Now that is not really likely, but what it does mean is that there should be less than average selling pressure on the stock considering the usually IPO accounts for 10% of shares released, while Palantir released over 20% based on the numbers provided above.\nWhere are we now? Well as per the study quoted earlier, we are right on track. The stock is selling off in an orderly fashion right before the lock-up period ends. Now we have to wait and see what the rebound looks like. Or does everyone sell high and try and buy even lower? It is a bit of a wait-and-see. Let's take a look at what the technicals show us.\nWhat Does The Price Say?\nTaking a quick peek at the technicals, we can see a couple of really strong support levels. Firstly, we broke through a pretty big one at $30 today and did so in a big way, which is a bit concerning in the short term, but there is potential for a quick bounce to re-test that $30 mark quickly. If these markets have taught us anything, it's that they can move quickly! In a normal case, this is probably where my stop would be. But have not had a position until today, the game changes a bit as I take on more risk.\n\n(Source: TC2000.com)\nWhen a stock as popular as Palantir tanks like we saw today, one of two things happens. Either the dip gets bought up and this stock will fly back up to $40, or we see Palantir drop down to ~$23. Because the stock is so new, we really do not have a good gauge for support. Looking below we can see roughly where I am pulling $23 out of. This is a pretty substantial move from here yet. Would be about 20% to the downside. If $23 breaks, it could go even further south.\n\n(Source: TC2000.com)\nWhen trying to catch the bounce, you have to be prepared to average down. It is a totally different approach. Scale in, and scale-out.... all while knowing when to cut it loose. If you want to play this safe, watch for the bounce and try and get in then. I do think there will be a decent bounce that takes the stock back to $36-$40, but the question is when. This is not a long-term hold for me personally.\nWrap-Up\nAs you can see, there is a lot to like about the direction in which the company is headed. The valuation can always be debated, but at the end of the day, the value is whatever someone is willing to pay for it. Palantir is a revenue machine and it is not going to slow down. They are playing with the \"big fish\" and the revenue will follow as long as they can continue to deliver on their goals. I am currently long, but watching closely as the lock-up period ends this week. If you are going long, make sure to scale in over the next couple of days and place your bets for which way this goes next week. Stay safe out there!","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386256351,"gmtCreate":1613189041273,"gmtModify":1704879338382,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Yes it's going up...","listText":"Yes it's going up...","text":"Yes it's going up...","images":[{"img":"https://static.tigerbbs.com/33b985e568e51d437d619d34446d48ad","width":"1080","height":"2709"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386256351","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":833601604,"gmtCreate":1629230684608,"gmtModify":1676529971900,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>it will go back up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>it will go back up!&nbsp;","text":"$Tiger Brokers(TIGR)$it will go back up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833601604","isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807304136,"gmtCreate":1627999273225,"gmtModify":1703499397388,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NFLX\">$Netflix(NFLX)$</a>just bought and it went down.... pray pray","listText":"<a href=\"https://laohu8.com/S/NFLX\">$Netflix(NFLX)$</a>just bought and it went down.... pray pray","text":"$Netflix(NFLX)$just bought and it went down.... pray pray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807304136","isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890824957,"gmtCreate":1628093271079,"gmtModify":1703501191249,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>up up up","listText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>up up up","text":"$fuboTV Inc.(FUBO)$up up up","images":[{"img":"https://static.tigerbbs.com/2bf6ab4001e1206871c1c405c4d0d3a4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890824957","isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":188425551,"gmtCreate":1623459738173,"gmtModify":1704204138323,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>is this a good buy ? what's the forecast of the growth?","listText":"<a href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>is this a good buy ? what's the forecast of the growth?","text":"$fuboTV Inc.(FUBO)$is this a good buy ? what's the forecast of the growth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188425551","isVote":1,"tweetType":1,"viewCount":441,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188460160,"gmtCreate":1623459005050,"gmtModify":1704204113144,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Hope for good news","listText":"Hope for good news","text":"Hope for good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188460160","repostId":"2142202973","repostType":4,"repost":{"id":"2142202973","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623447457,"share":"https://ttm.financial/m/news/2142202973?lang=&edition=fundamental","pubTime":"2021-06-12 05:37","market":"us","language":"en","title":"Novavax says COVID-19 vaccine shows immune response against Beta virus variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2142202973","media":"Reuters","summary":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune respo","content":"<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID-19 vaccine shows immune response against Beta virus variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID-19 vaccine shows immune response against Beta virus variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 05:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142202973","content_text":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.\nThe vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.\nNovavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.\nThe company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.\nHowever, the response against the Beta variant was slightly less, Novavax said.\nThe European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.\nThe company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.\n(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188484480,"gmtCreate":1623458950140,"gmtModify":1704204111369,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188484480","repostId":"1135185071","repostType":4,"repost":{"id":"1135185071","pubTimestamp":1623425954,"share":"https://ttm.financial/m/news/1135185071?lang=&edition=fundamental","pubTime":"2021-06-11 23:39","market":"us","language":"en","title":"Taiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1135185071","media":"Barron's","summary":"A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars to the most advanced components that power high-end phones, computers, and data centers.Taiwan Semiconductor Manufacturing sits at the nexus of this global chip renaissance. The company is a critical supplier to U.S. technology giants likeApple andQualcomm and Chinese companies like Huawei Technolog","content":"<p><img src=\"https://static.tigerbbs.com/dc1ac5d314c0b0f304bf6c78a0f2b0c7\" tg-width=\"1260\" tg-height=\"840\">A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars to the most advanced components that power high-end phones, computers, and data centers.</p>\n<p>Taiwan Semiconductor Manufacturing(ticker: TSM) sits at the nexus of this global chip renaissance. The company is a critical supplier to U.S. technology giants likeApple(AAPL) andQualcomm(QCOM) and Chinese companies like Huawei Technologies. TSMC’s stock is widely held across the globe, and for good reason. It has returned an annualized 29% over the past decade.</p>\n<p>But TSMC shares are now caught up in a rare correction. The stock is down 15% since mid-February. Investors should avoid the temptation to buy on the dip, at least for now. A confluence of factors could make the next couple of quarters bumpy enough to give long-term investors a chance to scoop up shares of the tech juggernaut at an even cheaper price.</p>\n<p>To be sure, the long-term opportunity hasn’t changed. If oil was the crucial commodity of the past,semiconductors are the critical commodity of the future—and TSMC is a leader in making the advanced chips needed for 5G, artificial intelligence, cloud computing, and electric vehicles.</p>\n<p>Founded in 1987, the Taiwanese company accounts for roughly 60% of outsourced chip manufacturing and 90% of the profits. TSMC has made significant investment in its foundries, helping it manufacture ever-denser chips that generate more power while using less energy. RivalIntel(INTC) has struggled to match that success.</p>\n<p>Even the lone analyst with a Sell rating on TSMC stock sings the company’s praises: “This is an A-plus company with solid management,” says Mehdi Hosseini, senior equity analyst at Susquehanna Financial Group, who has covered TSMC for more than 20 years. But Hosseini says he can’t ignore the near-term challenges and the pricey stock.</p>\n<p>Despite the recent selloff, TSMC shares are still up 110% over the past 12 months, and they trade at 27 times earnings estimates for the next 12 months, well above the stock’s five-year average of 19.</p>\n<p><img src=\"https://static.tigerbbs.com/f343f4fd4554dcc3a5fc6842713fd34c\" tg-width=\"685\" tg-height=\"429\">That elevated multiple doesn’t offer much cushion if and when challenges arise. Some money managers caution that near-term demand may not live up to analysts’ rosy forecasts for the next couple of quarters. Also, increased spending by TSMC and its rivals to meet a surge in demand could dent profit margins.</p>\n<p>Meanwhile, escalating geopolitical tensions put Taiwan, a self-ruled democracy that China considers a province, and its most important company in a fraught position.</p>\n<p>Daiwa Capital Markets analyst Rick Hsu is concerned that the chip shortage—which has hobbled automotive plants and sent gamers scrambling to find new consoles—could create inventory-related issues in the first half of 2022.</p>\n<p>Hsu told<i>Barron’s</i>in an email that TSMC’s stock needs to shed another 15%, to about $100, to adequately reflect the current risk profile. The stock recently closed at $118.</p>\n<p>Lackluster demand related to smartphones, which accounts for 45% of revenue, could also lead to disappointment. With TSMC profit margins already near a peak, future growth will require a boost in sales. That could be challenging in the near term. Apple’s iPhone 13 is unlikely to offer a major catalyst, while Chinese smartphone vendors don’t currently have the killer app needed to drive upgrades, Hosseini says.</p>\n<p>“You can’t just give it multiple expansion because it’s a great company. You need earnings power,” Hosseini says, noting that the company trades at a significant premium to theS&amp;P 500 index.He has a price target of $85, putting him far outside the consensus. Wall Street’s average price target on TSMC is $141.</p>\n<p>Analysts, on average, expect TSMC’s earnings to increase 14% to $4.06 a share this year, and 16% to $4.69 a share next year, with revenue growing 16% to $55.8 billion this year, and another 16% next year.</p>\n<p><b>Chips on the Table</b></p>\n<p>Shares of Taiwan Semiconductor Manufacturing have returned an annual average of 25% over the last decade.</p>\n<p><img src=\"https://static.tigerbbs.com/5615dee32fa47048e8747447b01257c9\" tg-width=\"663\" tg-height=\"272\"></p>\n<p>In April, TSMC CEO C.C. Wei told investors of a structural increase in demand, with megatrends around 5G and high-performance computing applications fueling strong demand for several years to come.</p>\n<p>Even so, Wall Street’s estimates may be too optimistic, says Laura Geritz, CEO of Rondure Global Advisors, which owns TSMC shares. She notes that growth at the company was boosted last year as quarantined families loaded up on PCs, gadgets, gaming consoles, and home appliances, all of which require more and more chips.</p>\n<p>Those buying patterns could quickly change as the pandemic eases and central banks begin to taper their support of the economy.</p>\n<p>“I think you will get a better shot,” Geritz says of buying TSMC stock. “It’s expensive when you strip away what could be fiscal and stay-at-home economics.”</p>\n<p>One of the reasons that investors are drawn to TSMC is its deep and impressive list of customers. But that advantage is becoming increasingly costly to maintain as companies—and governments—push for more geographically diverse supply chains.</p>\n<p>In the U.S., the Senate just passed a sweeping $250 billion China package that includes funding and incentives for producing more chips closer to home, along with calls for increased funding of research and development more broadly to help the U.S. maintain its technological edge against China.</p>\n<p>The Biden administration just completed a supply-chain review of critical materials—such as chips—and is pushing to spur more production at home and make the U.S. less vulnerable to global supply-chain disruptions.</p>\n<p>The industry is already reacting. Intel recently unveiled plans to spend $20 billion on two new manufacturing plants in Arizona, whileSamsung Electronics(005930.Korea) plans to invest $116 billion over the next decade, which includes a new chip factory in the U.S. Meanwhile, TSMC has said it plans to invest $100 billion over the next three years—including building two new factories of its own in Arizona.</p>\n<p>The companies’ increased spending is probably required to maintain a competitive edge, and the expenditure could address some of the Biden administration concerns by moving some production back to the U.S.</p>\n<p>In the near term, though, the spending creates financial risk. Longtime TSMC investor Andrew Foster earlier this year sold the TSMC stake he held in his $2.1 billionSeafarer Overseas Growth and Incomefund (SFGIX). He cites concerns about the company’s increased capital expenditure and its potential impact on free cash flow and the dividend, which has a yield of 1.8%.</p>\n<p>Current valuations don’t account for those risks, according to Foster, who says he may reconsider if the stock gets cheaper.</p>\n<p>In an email, TSMC representative Nina Kao said the company’s investment in Arizona is intended to support customers’ long-term capacity needs and isn’t related to political pressure. The company, Kao added, is confident that the Arizona factory will be profitable.</p>\n<p>The biggest risk to TSMC shares is China. The country is intent on unification, and tensions have escalated with China increasing military activity in the South China Sea region. Friction is likely to intensify: The U.S. has said it willsoon hold investment and trade talks with Taiwan,as the administration looks to strengthen Taipei.</p>\n<p>While policy watchers don’t see an armed conflict on the horizon, therisk of an accident is rising as military activity mounts. How to quantify TSMC’s China risk keeps money managers up at night. They say that a military conflict between China and Taiwan is an all-bets-are-off event that would rattle entire markets, not just TSMC stock.</p>\n<p>TSMC declined to comment on politics beyond stating that it was a “law-abiding company” focused on serving its customers.</p>\n<p>The risks don’t change the fact that semiconductors have never been more important.</p>\n<p>“Valuations in quality growth names such as TSMC have clearly gone up, in part because demand for semiconductors is elevated, while at the same time there is quite a serious shortage of them,” says Martin Lau, managing partner at $37 billion FSSA Investment Managers, which is focused on Asia-Pacific and emerging market strategies.</p>\n<p>And yet, “cyclically, this is not the best time to buy TSMC, and the near-term margin of safety has fallen,” he adds. “We remain positive in the longer term.”</p>\n<p>Investors just have to pick the right entry point.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaiwan Semiconductor Is the World’s Most Important Chip Maker. How to Play the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/taiwan-semi-stock-51623366589?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars ...</p>\n\n<a href=\"https://www.barrons.com/articles/taiwan-semi-stock-51623366589?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSM":"台积电"},"source_url":"https://www.barrons.com/articles/taiwan-semi-stock-51623366589?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135185071","content_text":"A severe shortage of semiconductors hascaused pain across the economy, but it’s also giving investors a new appreciation for the importance of semis—everything from simple chips costing a few dollars to the most advanced components that power high-end phones, computers, and data centers.\nTaiwan Semiconductor Manufacturing(ticker: TSM) sits at the nexus of this global chip renaissance. The company is a critical supplier to U.S. technology giants likeApple(AAPL) andQualcomm(QCOM) and Chinese companies like Huawei Technologies. TSMC’s stock is widely held across the globe, and for good reason. It has returned an annualized 29% over the past decade.\nBut TSMC shares are now caught up in a rare correction. The stock is down 15% since mid-February. Investors should avoid the temptation to buy on the dip, at least for now. A confluence of factors could make the next couple of quarters bumpy enough to give long-term investors a chance to scoop up shares of the tech juggernaut at an even cheaper price.\nTo be sure, the long-term opportunity hasn’t changed. If oil was the crucial commodity of the past,semiconductors are the critical commodity of the future—and TSMC is a leader in making the advanced chips needed for 5G, artificial intelligence, cloud computing, and electric vehicles.\nFounded in 1987, the Taiwanese company accounts for roughly 60% of outsourced chip manufacturing and 90% of the profits. TSMC has made significant investment in its foundries, helping it manufacture ever-denser chips that generate more power while using less energy. RivalIntel(INTC) has struggled to match that success.\nEven the lone analyst with a Sell rating on TSMC stock sings the company’s praises: “This is an A-plus company with solid management,” says Mehdi Hosseini, senior equity analyst at Susquehanna Financial Group, who has covered TSMC for more than 20 years. But Hosseini says he can’t ignore the near-term challenges and the pricey stock.\nDespite the recent selloff, TSMC shares are still up 110% over the past 12 months, and they trade at 27 times earnings estimates for the next 12 months, well above the stock’s five-year average of 19.\nThat elevated multiple doesn’t offer much cushion if and when challenges arise. Some money managers caution that near-term demand may not live up to analysts’ rosy forecasts for the next couple of quarters. Also, increased spending by TSMC and its rivals to meet a surge in demand could dent profit margins.\nMeanwhile, escalating geopolitical tensions put Taiwan, a self-ruled democracy that China considers a province, and its most important company in a fraught position.\nDaiwa Capital Markets analyst Rick Hsu is concerned that the chip shortage—which has hobbled automotive plants and sent gamers scrambling to find new consoles—could create inventory-related issues in the first half of 2022.\nHsu toldBarron’sin an email that TSMC’s stock needs to shed another 15%, to about $100, to adequately reflect the current risk profile. The stock recently closed at $118.\nLackluster demand related to smartphones, which accounts for 45% of revenue, could also lead to disappointment. With TSMC profit margins already near a peak, future growth will require a boost in sales. That could be challenging in the near term. Apple’s iPhone 13 is unlikely to offer a major catalyst, while Chinese smartphone vendors don’t currently have the killer app needed to drive upgrades, Hosseini says.\n“You can’t just give it multiple expansion because it’s a great company. You need earnings power,” Hosseini says, noting that the company trades at a significant premium to theS&P 500 index.He has a price target of $85, putting him far outside the consensus. Wall Street’s average price target on TSMC is $141.\nAnalysts, on average, expect TSMC’s earnings to increase 14% to $4.06 a share this year, and 16% to $4.69 a share next year, with revenue growing 16% to $55.8 billion this year, and another 16% next year.\nChips on the Table\nShares of Taiwan Semiconductor Manufacturing have returned an annual average of 25% over the last decade.\n\nIn April, TSMC CEO C.C. Wei told investors of a structural increase in demand, with megatrends around 5G and high-performance computing applications fueling strong demand for several years to come.\nEven so, Wall Street’s estimates may be too optimistic, says Laura Geritz, CEO of Rondure Global Advisors, which owns TSMC shares. She notes that growth at the company was boosted last year as quarantined families loaded up on PCs, gadgets, gaming consoles, and home appliances, all of which require more and more chips.\nThose buying patterns could quickly change as the pandemic eases and central banks begin to taper their support of the economy.\n“I think you will get a better shot,” Geritz says of buying TSMC stock. “It’s expensive when you strip away what could be fiscal and stay-at-home economics.”\nOne of the reasons that investors are drawn to TSMC is its deep and impressive list of customers. But that advantage is becoming increasingly costly to maintain as companies—and governments—push for more geographically diverse supply chains.\nIn the U.S., the Senate just passed a sweeping $250 billion China package that includes funding and incentives for producing more chips closer to home, along with calls for increased funding of research and development more broadly to help the U.S. maintain its technological edge against China.\nThe Biden administration just completed a supply-chain review of critical materials—such as chips—and is pushing to spur more production at home and make the U.S. less vulnerable to global supply-chain disruptions.\nThe industry is already reacting. Intel recently unveiled plans to spend $20 billion on two new manufacturing plants in Arizona, whileSamsung Electronics(005930.Korea) plans to invest $116 billion over the next decade, which includes a new chip factory in the U.S. Meanwhile, TSMC has said it plans to invest $100 billion over the next three years—including building two new factories of its own in Arizona.\nThe companies’ increased spending is probably required to maintain a competitive edge, and the expenditure could address some of the Biden administration concerns by moving some production back to the U.S.\nIn the near term, though, the spending creates financial risk. Longtime TSMC investor Andrew Foster earlier this year sold the TSMC stake he held in his $2.1 billionSeafarer Overseas Growth and Incomefund (SFGIX). He cites concerns about the company’s increased capital expenditure and its potential impact on free cash flow and the dividend, which has a yield of 1.8%.\nCurrent valuations don’t account for those risks, according to Foster, who says he may reconsider if the stock gets cheaper.\nIn an email, TSMC representative Nina Kao said the company’s investment in Arizona is intended to support customers’ long-term capacity needs and isn’t related to political pressure. The company, Kao added, is confident that the Arizona factory will be profitable.\nThe biggest risk to TSMC shares is China. The country is intent on unification, and tensions have escalated with China increasing military activity in the South China Sea region. Friction is likely to intensify: The U.S. has said it willsoon hold investment and trade talks with Taiwan,as the administration looks to strengthen Taipei.\nWhile policy watchers don’t see an armed conflict on the horizon, therisk of an accident is rising as military activity mounts. How to quantify TSMC’s China risk keeps money managers up at night. They say that a military conflict between China and Taiwan is an all-bets-are-off event that would rattle entire markets, not just TSMC stock.\nTSMC declined to comment on politics beyond stating that it was a “law-abiding company” focused on serving its customers.\nThe risks don’t change the fact that semiconductors have never been more important.\n“Valuations in quality growth names such as TSMC have clearly gone up, in part because demand for semiconductors is elevated, while at the same time there is quite a serious shortage of them,” says Martin Lau, managing partner at $37 billion FSSA Investment Managers, which is focused on Asia-Pacific and emerging market strategies.\nAnd yet, “cyclically, this is not the best time to buy TSMC, and the near-term margin of safety has fallen,” he adds. “We remain positive in the longer term.”\nInvestors just have to pick the right entry point.","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387581168,"gmtCreate":1613754675754,"gmtModify":1704884740157,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387581168","repostId":"2112849691","repostType":2,"repost":{"id":"2112849691","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1613751540,"share":"https://ttm.financial/m/news/2112849691?lang=&edition=fundamental","pubTime":"2021-02-20 00:19","market":"hk","language":"en","title":"Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2112849691","media":"Dow Jones","summary":"MW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine ","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n</p>\n<p>\n  Ciara Linnane \n</p>\n<p>\n  U.S. will commit $4 billion to the World Health Organization's Covax program \n</p>\n<p>\n  The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 110.4 million on Friday, as the leaders of the G-7 economies were scheduled to meet and discuss the effort to get COVID vaccines to the world's poorest countries. \n</p>\n<p>\n  The administration of President Joe Biden said it will commit $4 billion to the World Health Organization's Covax program, which aims to ensure vaccine equity for lower-income countries, which so far have been left behind as wealthier countries have snapped up the bulk of the vaccine supply. \n</p>\n<p>\n  The European Union said it will double its Covax funding to <a href=\"https://laohu8.com/S/AONE\">one</a> billion euros and pledged another 100 million that will be earmarked for African countries. In an interview with the Financial Times, French President Emmanuel Macron proposed that Western countries transfer 3% to 5% of their stock of vaccine to Africa. \n</p>\n<p>\n  The U.K. holds the G-7 presidency this year, and Prime Minister Boris Johnson is meeting virtually with the leaders of France, Germany, Italy, Canada, Japan and the United States to discuss international challenges -- chief among them the pandemic that has killed almost 2.5 million people around the world, the Associated Press reported . \n</p>\n<p>\n</p>\n<p>\n  The head of the United Nations on Thursday sharply criticized developed countries for hogging COVID-19 vaccines  and called for a global effort to get all people in all countries vaccinated as soon as possible. \n</p>\n<p>\n  UN Secretary-General António Guterres slammed the \"wildly uneven and unfair\" distribution of vaccines, with 10 countries administering 75% of all vaccinations to date, leaving 130 countries without a single dose. \n</p>\n<p>\n  Guterres comments echo those of World Health Organization Director-General Tedros Adhanom Ghebreyesus, who has repeatedly called on richer nations to join the WHO's Covax program,  which aims to ensure vaccine supply for lower-income countries. The agency says Covax needs $5 billion in funding in 2021 alone. \n</p>\n<p>\n  \"We need global leadership to scale up vaccine production and achieve vaccine equity,\" Tedros said in a joint statement issued last week with UNICEF Executive Director Henrietta Fore. \"COVID-19 has shown that our fates are inextricably linked. Whether we win or lose, we will do so together.\" \n</p>\n<p>\n  Don't miss: Hoarding the COVID vaccines is a losing strategy for rich nations  \n</p>\n<p>\n</p>\n<p>\n  On Friday, Tedros welcomed the new commitments to Covax. \n</p>\n<p>\n  \"This can't be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,\" he said in a statement.   \n</p>\n<p>\n  There was positive vaccine news from Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX), which said they are requesting a regulatory change to the storage requirements for their COVID-19 vaccine, as MarketWatch's Jaimy Lee reported . \n</p>\n<p>\n  Don't miss: Yes, your employer can require you to get a COVID-19 vaccine, the EEOC says  \n</p>\n<p>\n  The companies said they have new data showing their vaccine is still stable when stored in pharmaceutical freezers and refrigerators for up to two weeks, between the temperatures of negative 13 degrees Fahrenheit and 5 degrees Fahrenheit. Right now their vaccine must be stored in ultra-low temperature freezers between the temperatures of negative 112 degrees Fahrenheit and negative 76 degrees Fahrenheit. \n</p>\n<p>\n  \"The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,\" BioNTech CEO Ugur Sahin said in a statement. \n</p>\n<p>\n  Separately, Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> said it has submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. J&amp;J's vaccine will be reviewed by a group of vaccine experts next week as part of the U.S. Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. \n</p>\n<p>\n  A Mayo Clinic report found that both of the vaccines authorized for use in the U.S. -- the Pfizer/BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a> and a separate one developed by Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> that uses the same mRNA technology -- are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials. \n</p>\n<p>\n  The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. \n</p>\n<p>\n</p>\n<p>\n  In other news: \n</p>\n<p>\n  -- Life should return to normal -- more or less -- by Christmas, Dr. Anthony Fauci predicted Thursday. In an interview with MSNBC that things will start getting back to normal \"by the end of the year, by Christmas.\" It may not be exactly like pre-pandemic life, though. Fauci said theaters and restaurants will likely still have reduced capacity, and \"Maybe you'll still have to wear masks\" in public. \n</p>\n<p>\n  Read now: How COVID-19 is keeping kids away from the dentist -- especially children on Medicaid  \n</p>\n<p>\n  -- It's very rare for someone to get infected with the coronavirus causing the disease COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn't guaranteed  51 confirmed cases of reinfection along with roughly 11,000 suspected or probable reinfections. Reinfection is thought to occur when protective antibodies wane in people who have previously contracted the virus or in people who contracted the virus without developing antibodies. \n</p>\n<p>\n  --New York Gov. Andrew Cuomo, who was widely praised for his handling to the pandemic when his state was the epicenter last spring, is facing a growing chorus of criticism over his administration's failure   about his conversation with the governor. \n</p>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  February 19, 2021 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-02-20 00:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n</p>\n<p>\n  Ciara Linnane \n</p>\n<p>\n  U.S. will commit $4 billion to the World Health Organization's Covax program \n</p>\n<p>\n  The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 110.4 million on Friday, as the leaders of the G-7 economies were scheduled to meet and discuss the effort to get COVID vaccines to the world's poorest countries. \n</p>\n<p>\n  The administration of President Joe Biden said it will commit $4 billion to the World Health Organization's Covax program, which aims to ensure vaccine equity for lower-income countries, which so far have been left behind as wealthier countries have snapped up the bulk of the vaccine supply. \n</p>\n<p>\n  The European Union said it will double its Covax funding to <a href=\"https://laohu8.com/S/AONE\">one</a> billion euros and pledged another 100 million that will be earmarked for African countries. In an interview with the Financial Times, French President Emmanuel Macron proposed that Western countries transfer 3% to 5% of their stock of vaccine to Africa. \n</p>\n<p>\n  The U.K. holds the G-7 presidency this year, and Prime Minister Boris Johnson is meeting virtually with the leaders of France, Germany, Italy, Canada, Japan and the United States to discuss international challenges -- chief among them the pandemic that has killed almost 2.5 million people around the world, the Associated Press reported . \n</p>\n<p>\n</p>\n<p>\n  The head of the United Nations on Thursday sharply criticized developed countries for hogging COVID-19 vaccines  and called for a global effort to get all people in all countries vaccinated as soon as possible. \n</p>\n<p>\n  UN Secretary-General António Guterres slammed the \"wildly uneven and unfair\" distribution of vaccines, with 10 countries administering 75% of all vaccinations to date, leaving 130 countries without a single dose. \n</p>\n<p>\n  Guterres comments echo those of World Health Organization Director-General Tedros Adhanom Ghebreyesus, who has repeatedly called on richer nations to join the WHO's Covax program,  which aims to ensure vaccine supply for lower-income countries. The agency says Covax needs $5 billion in funding in 2021 alone. \n</p>\n<p>\n  \"We need global leadership to scale up vaccine production and achieve vaccine equity,\" Tedros said in a joint statement issued last week with UNICEF Executive Director Henrietta Fore. \"COVID-19 has shown that our fates are inextricably linked. Whether we win or lose, we will do so together.\" \n</p>\n<p>\n  Don't miss: Hoarding the COVID vaccines is a losing strategy for rich nations  \n</p>\n<p>\n</p>\n<p>\n  On Friday, Tedros welcomed the new commitments to Covax. \n</p>\n<p>\n  \"This can't be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,\" he said in a statement.   \n</p>\n<p>\n  There was positive vaccine news from Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX), which said they are requesting a regulatory change to the storage requirements for their COVID-19 vaccine, as MarketWatch's Jaimy Lee reported . \n</p>\n<p>\n  Don't miss: Yes, your employer can require you to get a COVID-19 vaccine, the EEOC says  \n</p>\n<p>\n  The companies said they have new data showing their vaccine is still stable when stored in pharmaceutical freezers and refrigerators for up to two weeks, between the temperatures of negative 13 degrees Fahrenheit and 5 degrees Fahrenheit. Right now their vaccine must be stored in ultra-low temperature freezers between the temperatures of negative 112 degrees Fahrenheit and negative 76 degrees Fahrenheit. \n</p>\n<p>\n  \"The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,\" BioNTech CEO Ugur Sahin said in a statement. \n</p>\n<p>\n  Separately, Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> said it has submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. J&amp;J's vaccine will be reviewed by a group of vaccine experts next week as part of the U.S. Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. \n</p>\n<p>\n  A Mayo Clinic report found that both of the vaccines authorized for use in the U.S. -- the Pfizer/BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a> and a separate one developed by Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> that uses the same mRNA technology -- are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials. \n</p>\n<p>\n  The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. \n</p>\n<p>\n</p>\n<p>\n  In other news: \n</p>\n<p>\n  -- Life should return to normal -- more or less -- by Christmas, Dr. Anthony Fauci predicted Thursday. In an interview with MSNBC that things will start getting back to normal \"by the end of the year, by Christmas.\" It may not be exactly like pre-pandemic life, though. Fauci said theaters and restaurants will likely still have reduced capacity, and \"Maybe you'll still have to wear masks\" in public. \n</p>\n<p>\n  Read now: How COVID-19 is keeping kids away from the dentist -- especially children on Medicaid  \n</p>\n<p>\n  -- It's very rare for someone to get infected with the coronavirus causing the disease COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn't guaranteed  51 confirmed cases of reinfection along with roughly 11,000 suspected or probable reinfections. Reinfection is thought to occur when protective antibodies wane in people who have previously contracted the virus or in people who contracted the virus without developing antibodies. \n</p>\n<p>\n  --New York Gov. Andrew Cuomo, who was widely praised for his handling to the pandemic when his state was the epicenter last spring, is facing a growing chorus of criticism over his administration's failure   about his conversation with the governor. \n</p>\n<p>\n  (MORE TO FOLLOW) Dow Jones Newswires\n</p>\n<p>\n  February 19, 2021 11:19 ET (16:19 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞","JNJ":"强生"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112849691","content_text":"MW UPDATE: Global case tally for COVID climbs above 110.4 million as G-7 gathers to discuss vaccine equity\n\n\n  Ciara Linnane \n\n\n  U.S. will commit $4 billion to the World Health Organization's Covax program \n\n\n  The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 110.4 million on Friday, as the leaders of the G-7 economies were scheduled to meet and discuss the effort to get COVID vaccines to the world's poorest countries. \n\n\n  The administration of President Joe Biden said it will commit $4 billion to the World Health Organization's Covax program, which aims to ensure vaccine equity for lower-income countries, which so far have been left behind as wealthier countries have snapped up the bulk of the vaccine supply. \n\n\n  The European Union said it will double its Covax funding to one billion euros and pledged another 100 million that will be earmarked for African countries. In an interview with the Financial Times, French President Emmanuel Macron proposed that Western countries transfer 3% to 5% of their stock of vaccine to Africa. \n\n\n  The U.K. holds the G-7 presidency this year, and Prime Minister Boris Johnson is meeting virtually with the leaders of France, Germany, Italy, Canada, Japan and the United States to discuss international challenges -- chief among them the pandemic that has killed almost 2.5 million people around the world, the Associated Press reported . \n\n\n\n\n  The head of the United Nations on Thursday sharply criticized developed countries for hogging COVID-19 vaccines  and called for a global effort to get all people in all countries vaccinated as soon as possible. \n\n\n  UN Secretary-General António Guterres slammed the \"wildly uneven and unfair\" distribution of vaccines, with 10 countries administering 75% of all vaccinations to date, leaving 130 countries without a single dose. \n\n\n  Guterres comments echo those of World Health Organization Director-General Tedros Adhanom Ghebreyesus, who has repeatedly called on richer nations to join the WHO's Covax program,  which aims to ensure vaccine supply for lower-income countries. The agency says Covax needs $5 billion in funding in 2021 alone. \n\n\n  \"We need global leadership to scale up vaccine production and achieve vaccine equity,\" Tedros said in a joint statement issued last week with UNICEF Executive Director Henrietta Fore. \"COVID-19 has shown that our fates are inextricably linked. Whether we win or lose, we will do so together.\" \n\n\n  Don't miss: Hoarding the COVID vaccines is a losing strategy for rich nations  \n\n\n\n\n  On Friday, Tedros welcomed the new commitments to Covax. \n\n\n  \"This can't be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,\" he said in a statement.   \n\n\n  There was positive vaccine news from Pfizer Inc. $(PFE)$ and its German partner BioNTech SE (BNTX), which said they are requesting a regulatory change to the storage requirements for their COVID-19 vaccine, as MarketWatch's Jaimy Lee reported . \n\n\n  Don't miss: Yes, your employer can require you to get a COVID-19 vaccine, the EEOC says  \n\n\n  The companies said they have new data showing their vaccine is still stable when stored in pharmaceutical freezers and refrigerators for up to two weeks, between the temperatures of negative 13 degrees Fahrenheit and 5 degrees Fahrenheit. Right now their vaccine must be stored in ultra-low temperature freezers between the temperatures of negative 112 degrees Fahrenheit and negative 76 degrees Fahrenheit. \n\n\n  \"The data submitted may facilitate the handling of our vaccine in pharmacies and provide vaccination centers an even greater flexibility,\" BioNTech CEO Ugur Sahin said in a statement. \n\n\n  Separately, Johnson & Johnson $(JNJ)$ said it has submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. J&J's vaccine will be reviewed by a group of vaccine experts next week as part of the U.S. Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. \n\n\n  A Mayo Clinic report found that both of the vaccines authorized for use in the U.S. -- the Pfizer/BioNTech one and a separate one developed by Moderna Inc. $(MRNA)$ that uses the same mRNA technology -- are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials. \n\n\n  The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. \n\n\n\n\n  In other news: \n\n\n  -- Life should return to normal -- more or less -- by Christmas, Dr. Anthony Fauci predicted Thursday. In an interview with MSNBC that things will start getting back to normal \"by the end of the year, by Christmas.\" It may not be exactly like pre-pandemic life, though. Fauci said theaters and restaurants will likely still have reduced capacity, and \"Maybe you'll still have to wear masks\" in public. \n\n\n  Read now: How COVID-19 is keeping kids away from the dentist -- especially children on Medicaid  \n\n\n  -- It's very rare for someone to get infected with the coronavirus causing the disease COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn't guaranteed  51 confirmed cases of reinfection along with roughly 11,000 suspected or probable reinfections. Reinfection is thought to occur when protective antibodies wane in people who have previously contracted the virus or in people who contracted the virus without developing antibodies. \n\n\n  --New York Gov. Andrew Cuomo, who was widely praised for his handling to the pandemic when his state was the epicenter last spring, is facing a growing chorus of criticism over his administration's failure   about his conversation with the governor. \n\n\n  (MORE TO FOLLOW) Dow Jones Newswires\n\n\n  February 19, 2021 11:19 ET (16:19 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387583889,"gmtCreate":1613754611841,"gmtModify":1704884739025,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387583889","repostId":"1100960455","repostType":4,"repost":{"id":"1100960455","pubTimestamp":1613717993,"share":"https://ttm.financial/m/news/1100960455?lang=&edition=fundamental","pubTime":"2021-02-19 14:59","market":"us","language":"en","title":"Palantir: Buy The Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1100960455","media":"Seeking Alpha","summary":"Summary\n\nPalantir posted solid revenue, but missed on earnings. The future forecast was a bit disapp","content":"<p>Summary</p>\n<ul>\n <li>Palantir posted solid revenue, but missed on earnings. The future forecast was a bit disappointing.</li>\n <li>Palantir is expecting 30% year-over-year revenue growth after posting 47% growth for 2020.</li>\n <li>Palantir continues to grow its client base across multiple industries.</li>\n <li>Palantir's lock-up period ends on February 19th. Place your bets!</li>\n</ul>\n<p>One of the hotter stocks as of late is recent Direct Listing, Palantir Technologies Inc. (PLTR). Some investors were expecting the company was expected to release blowout earnings today and fell short of that. The company did post incredible revenue growth, and the path forward looks bright as well. However, investors were disappointed with just how bright that picture is according to the company. The stock is falling leading up to the end of the lock-up period as expected. Next week will tell a better story as to where this stock is headed. If you are feeling risky, jump aboard.</p>\n<p><b>Who Are They?</b></p>\n<p>If you are like me, you likely had no idea who this company was or what they did. Well, Palantir Technologies Inc. has been around since 2003 and is headquartered in Denver, Colorado. In short,they build and deploy software platforms for the intelligence community in the USA to assist in counterterrorism investigations and operations.</p>\n<p>Palantir Gothamis a software program that identifies patterns hidden deep within datasets. This helps execute real-world responses to threats that have been identified within the platform. This was used in the efforts to help those in need in hurricane Florence in 2018. Palantir Gothamcombined publicly available flood data with weather information and social vulnerability census data to find the communities in greatest needand resources were deployed appropriately. More recently, they are providing the U.S. government with coronavirus tracking software.</p>\n<p>The company also provides Palantir Foundry,a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place.</p>\n<p>Pretty cool hey?</p>\n<p><b>What Is Driving The Company?</b></p>\n<p>Revenue. This is a growth play, plain and simple. Looking below we can see what is forecasted down the pipe. The missing block is 2020, which we found out todaywas $1.1 billion. That is a ~47% increase year-over-year. Going forward, analysts are projecting the pace stays heavy at 35%+ per year revenue growth. Often we consider 20% being strong, so that makes this look really good. For the fourth quarter, the company posted $322.1 million in revenue for the quarter, which was a beat by 20%.</p>\n<p><img src=\"https://static.tigerbbs.com/2926257ca97794e55159ce8c6021a745\" tg-width=\"2978\" tg-height=\"992\"></p>\n<p>(Source: TIKR.com)</p>\n<p>The shock came from theloss per share which totaled $0.08 versus the positive $0.02 consensus. The stock fell over 12% today on the earnings news. Upon diving deeper, it would appear most investors were disappointed with the forward forecasts. I personally think they are sandbagging a bit to blow away consensus down the line, but time will tell how true that is. Based on everything the company had put out in terms of news, which is nicely outlined inJohn Rhodes article : Palantir: Potential Q4 Revenue Blowoutmost people expected the revenue beat, but the action in the stock over the last week showed otherwise.</p>\n<p>Data has become more relevant to the average person than ever before. The local news has all kinds of data on it when it comes to COVID-19.In 2020, Palantir helped 100 commercial organizations and 10 national governments respond to COVID-19. This has been a large opportunity for Palantir, and they have not squandered it. This response has helped earn thema 2-year contract for U.K. health services work worth $31.5 million. In the fourth quarter alone, the company signed21 deals worth more than $5 million. 12 of which were worth $10 million or more. Revenue growth will continue to be the future of Palantir.</p>\n<p>Some of the best business going is government business. For the year, Palantir saw56% of their revenue or $610 million come from government contracts. While the commercial side saw higher year-over-year growth at 107%, a 77% increase in government-based revenue isn't anything to laugh at. One of the more impressive pieces was that we saw happen with the average customer.Revenue increased by 41% year-over-year. Up to $7.9 million per customer from $5.6 million. This is an important metric to keep an eye on as customers hand more and more business over to Palantir as they continue to develop and improve their systems. The other factor playing into this is Palantir pulling larger customers into the fold. The new customers acquired in 2020, generated $42 million in revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/9284f5fd3e26d0c55fcd9b2f6355371e\" tg-width=\"1752\" tg-height=\"983\"></p>\n<p>(Company Presentation)</p>\n<p>So all of this and we still sit down 12% today? As I mentioned above, it was the forward forecasts that people were a bit shocked at. Palantir said toexpect revenue growth in excess of 30% for 2021. This would be fantastic news for most companies, but after you just posted a 47% growth year, it is a bit saddening. But as I said, I think they are sandbagging a bit. Analysts are still projecting about a 35% increase for 2021. Something tells me they will outdo that as the year goes on. The company did state that they are targeting $4 billion in revenue by 2025, which carrying 30% per year growth from here will get you. I fully expect that number to creep closer to $5 billion based on current projections. Palantir is going after the \"big fish\" across multiple industries.8 of their customers fall into the Fortune 100, and 12 of the Global 100. As their products continue to develop and improve, their bottom line is only going to get better. I think there is a lot of room to run here in the long term.</p>\n<p><b>What Are The Risks?</b></p>\n<p>One of the up-and-coming risks is the lock-up period ending, which I will touch on below. Besides that, I will look at the government contracts. Yes, they are some of the most important, but that's not to say they come without risk. In the past, Palantir has said they need to focus more so on commercial customers to help the bottom line and to turn a profit (part of the reason for the earnings sell-off). As we can see, they have landed some big-time commercial clients, but that government aspect still exists.</p>\n<p>Something to keep in mind as well is that dealing with the government can lead to crossing some lines that some are not okay with. As reported by the Washington Post,in 2018, more than 200 employees signed a letter to CEO Alex Karp, citing concerns over a partnership with Immigration and Customs Enforcement. Multiple other big tech companies have been forced to cut ties with government agencies in the past over potential human rights violations.</p>\n<p>That said, I do really think the company will continue to do very well in the commercial sector and well reduce the overall government exposure overtime.</p>\n<p><b>What's The \"Lock-Up Period\"?</b></p>\n<p>The one concern many have had with Palantir is the lock-up period, which ends on February 19th (Friday). Typically, this is where we will see the lows kick in on IPO's that go this route, but it is not always the case.</p>\n<blockquote>\n Looking at 15 stocks that sawtheir lock-up periods expire in the first two weeks of October, the majority of shares started to fall in the days before the expiration date, prior to bouncing back three to five days afterwards. However, some saw virtually no selling pressure on the day and the share price immediately climbed once the lock-up had ended.\n</blockquote>\n<p>What is it? Well in short, instead of an IPO where new shares of the company are created and are underwritten by an intermediary, we have a Direct Listing. This is wherethe business sells shares directly to the public without the help of any intermediaries. It does not involve any underwriters or other intermediaries, there are no new shares issued. This means the largest shareholders in the business can only freely sell their shares after the IPO lock-up expiration. Spotify (SPOT) and Slack (WORK) are two examples of companies that went the Direct Listing route. That said, neither of these companies had lock-up periods for employees.</p>\n<p>So what does this mean? Well, given thatMarketWatch said:</p>\n<blockquote>\n For Palantir, though, years of venture-capital investments have created more than enough shares to launch public trading: roughly 1.64 billion, though that grows to 2.17 billion in a fully diluted formula that includes vesting options.\n</blockquote>\n<p>It means that with roughly 497 million current outstanding shares, that we could see about 1.7 billion shares hit the market. Now that is not really likely, but what it does mean is that there should be less than average selling pressure on the stock considering the usually IPO accounts for 10% of shares released, while Palantir released over 20% based on the numbers provided above.</p>\n<p>Where are we now? Well as per the study quoted earlier, we are right on track. The stock is selling off in an orderly fashion right before the lock-up period ends. Now we have to wait and see what the rebound looks like. Or does everyone sell high and try and buy even lower? It is a bit of a wait-and-see. Let's take a look at what the technicals show us.</p>\n<p><b>What Does The Price Say?</b></p>\n<p>Taking a quick peek at the technicals, we can see a couple of really strong support levels. Firstly, we broke through a pretty big one at $30 today and did so in a big way, which is a bit concerning in the short term, but there is potential for a quick bounce to re-test that $30 mark quickly. If these markets have taught us anything, it's that they can move quickly! In a normal case, this is probably where my stop would be. But have not had a position until today, the game changes a bit as I take on more risk.</p>\n<p><img src=\"https://static.tigerbbs.com/6b568bf73db2c1b38aaa1546a10427dc\" tg-width=\"3837\" tg-height=\"1813\"></p>\n<p>(Source: TC2000.com)</p>\n<p>When a stock as popular as Palantir tanks like we saw today, one of two things happens. Either the dip gets bought up and this stock will fly back up to $40, or we see Palantir drop down to ~$23. Because the stock is so new, we really do not have a good gauge for support. Looking below we can see roughly where I am pulling $23 out of. This is a pretty substantial move from here yet. Would be about 20% to the downside. If $23 breaks, it could go even further south.</p>\n<p><img src=\"https://static.tigerbbs.com/3e3505c465c407b7387cbedf16a1b233\" tg-width=\"3840\" tg-height=\"1808\"></p>\n<p>(Source: TC2000.com)</p>\n<p>When trying to catch the bounce, you have to be prepared to average down. It is a totally different approach. Scale in, and scale-out.... all while knowing when to cut it loose. If you want to play this safe, watch for the bounce and try and get in then. I do think there will be a decent bounce that takes the stock back to $36-$40, but the question is when. This is not a long-term hold for me personally.</p>\n<p><b>Wrap-Up</b></p>\n<p>As you can see, there is a lot to like about the direction in which the company is headed. The valuation can always be debated, but at the end of the day, the value is whatever someone is willing to pay for it. Palantir is a revenue machine and it is not going to slow down. They are playing with the \"big fish\" and the revenue will follow as long as they can continue to deliver on their goals. I am currently long, but watching closely as the lock-up period ends this week. If you are going long, make sure to scale in over the next couple of days and place your bets for which way this goes next week. Stay safe out there!</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Buy The Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Buy The Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-19 14:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4406809-palantir-buy-the-dip><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir posted solid revenue, but missed on earnings. The future forecast was a bit disappointing.\nPalantir is expecting 30% year-over-year revenue growth after posting 47% growth for 2020.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4406809-palantir-buy-the-dip\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4406809-palantir-buy-the-dip","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100960455","content_text":"Summary\n\nPalantir posted solid revenue, but missed on earnings. The future forecast was a bit disappointing.\nPalantir is expecting 30% year-over-year revenue growth after posting 47% growth for 2020.\nPalantir continues to grow its client base across multiple industries.\nPalantir's lock-up period ends on February 19th. Place your bets!\n\nOne of the hotter stocks as of late is recent Direct Listing, Palantir Technologies Inc. (PLTR). Some investors were expecting the company was expected to release blowout earnings today and fell short of that. The company did post incredible revenue growth, and the path forward looks bright as well. However, investors were disappointed with just how bright that picture is according to the company. The stock is falling leading up to the end of the lock-up period as expected. Next week will tell a better story as to where this stock is headed. If you are feeling risky, jump aboard.\nWho Are They?\nIf you are like me, you likely had no idea who this company was or what they did. Well, Palantir Technologies Inc. has been around since 2003 and is headquartered in Denver, Colorado. In short,they build and deploy software platforms for the intelligence community in the USA to assist in counterterrorism investigations and operations.\nPalantir Gothamis a software program that identifies patterns hidden deep within datasets. This helps execute real-world responses to threats that have been identified within the platform. This was used in the efforts to help those in need in hurricane Florence in 2018. Palantir Gothamcombined publicly available flood data with weather information and social vulnerability census data to find the communities in greatest needand resources were deployed appropriately. More recently, they are providing the U.S. government with coronavirus tracking software.\nThe company also provides Palantir Foundry,a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place.\nPretty cool hey?\nWhat Is Driving The Company?\nRevenue. This is a growth play, plain and simple. Looking below we can see what is forecasted down the pipe. The missing block is 2020, which we found out todaywas $1.1 billion. That is a ~47% increase year-over-year. Going forward, analysts are projecting the pace stays heavy at 35%+ per year revenue growth. Often we consider 20% being strong, so that makes this look really good. For the fourth quarter, the company posted $322.1 million in revenue for the quarter, which was a beat by 20%.\n\n(Source: TIKR.com)\nThe shock came from theloss per share which totaled $0.08 versus the positive $0.02 consensus. The stock fell over 12% today on the earnings news. Upon diving deeper, it would appear most investors were disappointed with the forward forecasts. I personally think they are sandbagging a bit to blow away consensus down the line, but time will tell how true that is. Based on everything the company had put out in terms of news, which is nicely outlined inJohn Rhodes article : Palantir: Potential Q4 Revenue Blowoutmost people expected the revenue beat, but the action in the stock over the last week showed otherwise.\nData has become more relevant to the average person than ever before. The local news has all kinds of data on it when it comes to COVID-19.In 2020, Palantir helped 100 commercial organizations and 10 national governments respond to COVID-19. This has been a large opportunity for Palantir, and they have not squandered it. This response has helped earn thema 2-year contract for U.K. health services work worth $31.5 million. In the fourth quarter alone, the company signed21 deals worth more than $5 million. 12 of which were worth $10 million or more. Revenue growth will continue to be the future of Palantir.\nSome of the best business going is government business. For the year, Palantir saw56% of their revenue or $610 million come from government contracts. While the commercial side saw higher year-over-year growth at 107%, a 77% increase in government-based revenue isn't anything to laugh at. One of the more impressive pieces was that we saw happen with the average customer.Revenue increased by 41% year-over-year. Up to $7.9 million per customer from $5.6 million. This is an important metric to keep an eye on as customers hand more and more business over to Palantir as they continue to develop and improve their systems. The other factor playing into this is Palantir pulling larger customers into the fold. The new customers acquired in 2020, generated $42 million in revenue.\n\n(Company Presentation)\nSo all of this and we still sit down 12% today? As I mentioned above, it was the forward forecasts that people were a bit shocked at. Palantir said toexpect revenue growth in excess of 30% for 2021. This would be fantastic news for most companies, but after you just posted a 47% growth year, it is a bit saddening. But as I said, I think they are sandbagging a bit. Analysts are still projecting about a 35% increase for 2021. Something tells me they will outdo that as the year goes on. The company did state that they are targeting $4 billion in revenue by 2025, which carrying 30% per year growth from here will get you. I fully expect that number to creep closer to $5 billion based on current projections. Palantir is going after the \"big fish\" across multiple industries.8 of their customers fall into the Fortune 100, and 12 of the Global 100. As their products continue to develop and improve, their bottom line is only going to get better. I think there is a lot of room to run here in the long term.\nWhat Are The Risks?\nOne of the up-and-coming risks is the lock-up period ending, which I will touch on below. Besides that, I will look at the government contracts. Yes, they are some of the most important, but that's not to say they come without risk. In the past, Palantir has said they need to focus more so on commercial customers to help the bottom line and to turn a profit (part of the reason for the earnings sell-off). As we can see, they have landed some big-time commercial clients, but that government aspect still exists.\nSomething to keep in mind as well is that dealing with the government can lead to crossing some lines that some are not okay with. As reported by the Washington Post,in 2018, more than 200 employees signed a letter to CEO Alex Karp, citing concerns over a partnership with Immigration and Customs Enforcement. Multiple other big tech companies have been forced to cut ties with government agencies in the past over potential human rights violations.\nThat said, I do really think the company will continue to do very well in the commercial sector and well reduce the overall government exposure overtime.\nWhat's The \"Lock-Up Period\"?\nThe one concern many have had with Palantir is the lock-up period, which ends on February 19th (Friday). Typically, this is where we will see the lows kick in on IPO's that go this route, but it is not always the case.\n\n Looking at 15 stocks that sawtheir lock-up periods expire in the first two weeks of October, the majority of shares started to fall in the days before the expiration date, prior to bouncing back three to five days afterwards. However, some saw virtually no selling pressure on the day and the share price immediately climbed once the lock-up had ended.\n\nWhat is it? Well in short, instead of an IPO where new shares of the company are created and are underwritten by an intermediary, we have a Direct Listing. This is wherethe business sells shares directly to the public without the help of any intermediaries. It does not involve any underwriters or other intermediaries, there are no new shares issued. This means the largest shareholders in the business can only freely sell their shares after the IPO lock-up expiration. Spotify (SPOT) and Slack (WORK) are two examples of companies that went the Direct Listing route. That said, neither of these companies had lock-up periods for employees.\nSo what does this mean? Well, given thatMarketWatch said:\n\n For Palantir, though, years of venture-capital investments have created more than enough shares to launch public trading: roughly 1.64 billion, though that grows to 2.17 billion in a fully diluted formula that includes vesting options.\n\nIt means that with roughly 497 million current outstanding shares, that we could see about 1.7 billion shares hit the market. Now that is not really likely, but what it does mean is that there should be less than average selling pressure on the stock considering the usually IPO accounts for 10% of shares released, while Palantir released over 20% based on the numbers provided above.\nWhere are we now? Well as per the study quoted earlier, we are right on track. The stock is selling off in an orderly fashion right before the lock-up period ends. Now we have to wait and see what the rebound looks like. Or does everyone sell high and try and buy even lower? It is a bit of a wait-and-see. Let's take a look at what the technicals show us.\nWhat Does The Price Say?\nTaking a quick peek at the technicals, we can see a couple of really strong support levels. Firstly, we broke through a pretty big one at $30 today and did so in a big way, which is a bit concerning in the short term, but there is potential for a quick bounce to re-test that $30 mark quickly. If these markets have taught us anything, it's that they can move quickly! In a normal case, this is probably where my stop would be. But have not had a position until today, the game changes a bit as I take on more risk.\n\n(Source: TC2000.com)\nWhen a stock as popular as Palantir tanks like we saw today, one of two things happens. Either the dip gets bought up and this stock will fly back up to $40, or we see Palantir drop down to ~$23. Because the stock is so new, we really do not have a good gauge for support. Looking below we can see roughly where I am pulling $23 out of. This is a pretty substantial move from here yet. Would be about 20% to the downside. If $23 breaks, it could go even further south.\n\n(Source: TC2000.com)\nWhen trying to catch the bounce, you have to be prepared to average down. It is a totally different approach. Scale in, and scale-out.... all while knowing when to cut it loose. If you want to play this safe, watch for the bounce and try and get in then. I do think there will be a decent bounce that takes the stock back to $36-$40, but the question is when. This is not a long-term hold for me personally.\nWrap-Up\nAs you can see, there is a lot to like about the direction in which the company is headed. The valuation can always be debated, but at the end of the day, the value is whatever someone is willing to pay for it. Palantir is a revenue machine and it is not going to slow down. They are playing with the \"big fish\" and the revenue will follow as long as they can continue to deliver on their goals. I am currently long, but watching closely as the lock-up period ends this week. If you are going long, make sure to scale in over the next couple of days and place your bets for which way this goes next week. Stay safe out there!","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386256351,"gmtCreate":1613189041273,"gmtModify":1704879338382,"author":{"id":"3564012453009781","authorId":"3564012453009781","name":"Frozenize","avatar":"https://static.tigerbbs.com/38e2bafb389213c3b4323c432f3a77ca","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564012453009781","authorIdStr":"3564012453009781"},"themes":[],"htmlText":"Yes it's going up...","listText":"Yes it's going up...","text":"Yes it's going up...","images":[{"img":"https://static.tigerbbs.com/33b985e568e51d437d619d34446d48ad","width":"1080","height":"2709"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386256351","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}